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Abstract
Acute cerebral ischaemic injury results in increased neurotransmitter release which 
can result in cell death via receptor and non-receptor mediated mechanisms. 
Furthermore a delayed apoptotic response has been described which may be attributed 
to the CD95 death receptor. Using the murine hippocampal HT22 cell line, this study 
has developed a novel FRET construct to investigate the biochemical pathways 
associated with two models o f stroke induced neurotoxicity; CD95-induced apoptosis 
and glutamate-induced oxidative toxicity. CD95-induced apoptosis resulted in 
chromatin condensation and caspase activation which if inhibited rescued cells from 
death. Mitochondrial involvement was identified by cytochrome c release following 
CD95 stimulation. Furthermore the pro-apoptotic protein Bax was shown to be 
conformationally active and translocated to the mitochondrial following CD95 
stimulation indicating Bax mediated cytochrome c release. The novel DsRed-EYFP 
FRET construct which showed caspase activity in living cells and further in vitro 
analysis confirmed loss o f acceptor fluorescence was due to construct cleavage. 
Oxidative glutamate toxicity^ was shown to be mediated by calpains (calcium 
dependent proteases) and furthermore it was shown that the caspases contribute to the 
survival o f the cell. Investigation into the role o f the stress associated MAP kinase 
(SAPK/JNK) resulted in abnormal nuclear morphologies which were shown to be the 
result o f cell cycle arrest. Inhibition o f not only JNK but also glycogen synthase 
kinase (GSK) and calpains resulted in cell cycle arrest in the G2 or pre-mitotic cell 
cycle phase. In conclusion we have described a model where glutamate induced ROS 
production damages vital cellular components resulting in the activation o f the cell 
cycle. Upon progression through the cell cycle the damage is identified and the cells 
enter a caspase independent, calpain mediated cell death programme.
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1 INTRODUCTION
1.1 Cell Death Pathways: An Overview
Initial research into cell death pathways attempted to classify discrete pathways, the 
major forms of which were ‘programmed cell death’, or apoptosis an energy requiring 
process where the cell breaks down following a programmed sequence o f events and 
the activation of cell death proteases known as caspases. The second pathway was 
described as a passive form o f cell death where the events are not controlled, resulting 
in swelling and release of cellular components into the surrounding tissue. Classically 
this passive form of cell death will not utilise caspase activity but instead involves 
another group o f death associated proteases, calpains.
More recently, within the bracket of ‘necrosis’ other cell death programmes have been 
described including autophagic cell death, where cell components are degraded within 
characteristic compartments called autophagosomes, (Edinger and Thompson 2004; 
Gozuacik and Kimchi 2004; Yu et al. 2004a) and programmed forms o f necrosis 
which can involve caspase activation (Kitanaka and Kuchino 1999; Niquet et al. 2003; 
Proskuryakov et al. 2003). However, the presence of clearly defined cell death 
pathways is often disputed and a common view now is that the course o f cell decay is 
often dependent on the circumstances surrounding it and may display multiple 
features o f the classical apoptotic and necrotic pathways.
Figure 1.1 Morphological features of dying cells
Electron microscopy images o f untreated (a), autophagic (b), apoptotic (c) and 
necrotic (d) cells (Taken from Edinger and Thompson 2004). Autophagic cells are 
characterised by the presence o f vacuoles (autophagosomes) which are formed as the 
cell digests itself. Apoptotic cells show outer membrane integrity with clear 
chromatin condensation whereas necrotic cells show a loss of membrane integrity and 
swelling o f intracellular organelles.
1.2 Apoptosis
Apoptosis is a programmed form o f cell suicide, involving the activation of proteins 
that actively contribute to the demise of the cell. In a physiological context the foetus 
gives one o f the most well known examples of ‘programmed’ cell death where 
apoptosis is responsible for the formation o f fingers and toes by eliminating the tissue 
in bebA'een individual digits (Cecconi et al. 1998). In adulthood, apoptosis is 
predominantly responsible for the removal o f damaged cells, such as infected cells or 
those with irrevocably damaged DNA, which would otherwise cause damage to the 
organism as a whole. The advantage o f a programmed cell breakdown over that of, 
for example necrosis, is that cells undergoing apoptosis are broken down in an 
organised manner resulting in the formation o f small cellular “packages” which can 
be taken up and degraded by surrounding cells (see Figure 1.2),
Apoptosis may be mediated internally via DNA damage, resulting in the activation of 
proteins such as p53, or externally via death receptors such as CD95 (Fas, APO-1) or 
tumour necrosis factor a  (TNFa), which ultimately result in • the organised 
disassembly of the cell. Morphologically, one o f the first features observed is nuclear 
condensation, followed by fragmentation. Degradation of cellular components by 
apoptotic proteases known as ‘caspases’ (cysteinyl aspartate-specific proteases) 
results in the loss of cell structure, and the formation of apoptotic bodies which allow 
surrounding cells to take up, degrade and reuse the components of the dying cell (see 
Figure 1.2).
Death receptor ligand 
Growth factor withdrawal 
Radiation Debris uptake by 
surrounding cells
N uclear 
con d en sation
R e le a se  of 
mitochondrial proteins
Apoptosis
Blebbing
Breakdown of cellular 
com p onents
Figure 1.2: Apoptotic cell breakdown.
Upon apoptotic stimuli death associated proteases are activated which contribute to 
the breakdown of cellular components. Mitochondrial proteins such as cytochrome c 
and SMAC/DIABLO will be released into the cytosol and chromatin will condense 
and fragment. Visually the cell will show signs of'b lebbing ' as apoptotic bodies are 
formed which in turn are taken up by surrounding cells and degraded.
Although classical apoptosis is distinctly different from necrosis, the boundaries o f 
the two cell death processes have become blurred as certain t)'pes of cell death are 
discovered which show features o f both classical apoptosis and necrosis (Benchoua et 
al. 2001; Wang et al. 2003).
1.2.1 Inducers of Apoptosis
Apoptosis, being a programmed form of cell death immediately suggests the 
requirement o f an inducer or an activating mechanism. As mentioned above, 
apoptosis may be initiated by many different mechanisms which activate either an 
intrinsic pathway where apoptosis is activated from within the cell e.g. through 
chemicals such as staurosporine, DNA damage through radiation, or an extrinsic 
pathway where apoptosis may be initiated via an external death receptor e.g. during an 
immune response.
1.2.1.1 Staurosporine
Staurosporine is a widely used example o f a chemical apoptotic inducer. Other 
examples include etoposide and methotrexate (Kruman et al. 2004). Originally 
identified as an antibiotic, staurosporine is now widely used to study apoptosis. 
Unlike etoposide and methotrexate however, staurosporine does not damage DNA, 
instead the toxic effect o f staurosporine is brought about by its inhibition of cellular 
kinases. These include protein kinase C and tyrosine kinases (Koh et al. 1995) the 
inhibition of which prevents normal cellular flmction and induces a series of apoptotic 
events including DNA condensation, fragmentation, Bax translocation and activation, 
cytochrome c release and caspase activity (Desagher et al. 1999; Rehm et al. 2002).
1.2.1.2 Death Receptors
Death receptors are part of an extrinsic pathway where other cells can signal either 
directly, such as T cell signalling, or indirectly via the release of cytokines to initiate 
apoptosis in another cell. Several different death receptors have been identified, these 
include CD95 (Fas/APO-1), tumour necrosis factor-related apoptosis inducing ligand 
receptor (TRAIL) receptor-1 (DR4), TRAIL-R2 (DR5) and tumour necrosis factor 
receptor-1 (TNFR-1). Basic mechanisms of apoptotic induction appear to be similar 
between death receptors, involving an internal ‘death domain’ (DD) which recruits 
and activates caspases via a ‘death effector domain’ (DED) (see Figure 1.3) (Thorburn 
2004). One of the most widely studied o f death receptors is CD95.
1.2.1.3 CD95 Receptor
The CD95 (Fas, APO-1) death receptor is a member of the tumour necrosis factor 
(TNF) family o f death receptors. It has been studied in a variety o f cell lines and 
tissues in vivo where its primary function appears to be the induction o f apoptosis. 
The CD95 death receptor is most widely used in the elimination of autoreactive T and 
B cells during the generation of the immune system. However, CD95 is also 
expressed in many other tissues such as liver (Watanabe-Fukunaga et al, 1992; Yin et 
al. 1999) and brain (Jin et al. 2001; Yew et al. 2004).
Plasm a membrane
Death effector f 
domain (DED) 1
Death domain containing 
ca sp a se  eg . casp ase-8 /-  
10 (or FLIP)
Death receptor ligand/cytokine
Death domain (DD) e.g . FADD
Figure 1.3: Interaction of death receptors with caspases.
Upon binding o f the ligand the death receptor trimerises. Internally a death effector 
domain (DED) associates and recruits a death domain (DD) containing caspase such 
as caspase-8 or -10 and associates via a homologous death domain present on the 
death effector domain and caspase.
The CD95 ligand (CD95L) binds trimerically to the CD95 receptor and activates the 
internal CD95 associated death domain (FADD) via homotj'pic interaction between 
conserved death domain surfaces in the cytoplasmic region of CD95 and in FADD 
(see Figure 1.3) (Hill et al. 2004), This is the first step in the formation o f the death 
inducing signalling complex (DISC). Once bound, FADD then associates with 
caspases 8 and 10 (Kischkel et al. 1995; Peter and Krammer 2003) via a second 
homotypic interaction known as the death effector domain (DED) present on FADD 
and caspases-8 and 10. Once recruited, caspase-8 is thought to be activated via an 
autoproteolytic cascade triggered by the presence o f many caspase molecules at the 
DISC (Muzio et al. 1998). Other studies have shown that c-FL IP l, an inactive 
homologue of caspase-8/-10, may be recruited and used to activate caspase-8 via a 
homotypic DED interaction (Chang et al. 2002). Indeed, c-FLIP knockout mice show 
a phenotype similar to that of caspase-8 knockouts (Yeh et al. 2000). However, the 
role o f c-FLIPl remains controversial as further studies have shown its presence at the 
DISC to be inhibitory (Tschopp et al. 1998; Peter and Krammer 2003).
A parallel apoptotic pathway was described by Yang and co-workers upon the 
discoveiy o f Daxx (Yang et al. 1997). Daxx was shown to interact with CD95 and 
upon co-transfection with CD95 apoptosis was significantly increased. However the 
role o f Daxx as a pro-apoptotic interacting protein in CD95-induced apoptosis was 
questioned when Michaelson and co-workers created Daxx deficient mice 
(Michaelson et al. 1999). Daxx knockout mice died by day 9.5 of gestation due to 
significant levels o f apoptosis which implicated Daxx as an essential protein during 
development and in the prevention of apoptosis. The lack of a parallel pathway was
also shown by Zhang and co-workers who showed that T cells from mice lacking 
FADD were completely resistant to FADD-induced apoptosis (Zhang et al. 1998).
The ability of the cell to activate caspase-8 at this level is thought to be one of the 
factors determining whether the cell is type I or type II. It has been proposed that type 
I cells are able to produce large enough quantities o f caspase-8 at the DISC to result in 
the direct activation o f caspase-3 leading the cell directly into apoptosis, independent 
o f mitochondrial involvement. Type II or mitochondrial dependent cells are those 
which are dependent on the activation o f the mitochondrial pathway. Type II cells 
also recruit and activate caspase-8 however, at much lower levels. Therefore the 
activation of caspase-3 requires the release o f mitochondrial proteins including 
cytochrome c and Bid cleavage. This results in the activation o f Apaf-1, caspase-9 
and subsequent activation o f caspase-3 (See Figure 1.6) (Scaffidi et al. 1998; 
Budihardjo et al. 1999). Despite the two cell types being mitochondrial dependent or 
independent, mitochondrial involvement can be detected in both (Scaffidi et al. 1998). 
However, it is only through inhibition o f mitochondrial involvement by 
overexpression of Bcl-2 or B c 1-Xl that reveals the cell type as only type II 
(mitochondrially dependent cells) will be inhibited by B cI -2 /B c 1-Xl overexpression.
The type I/type II model was challenged by Strasser and co-workers who 
demonstrated that previous data indicating two pathways may have arisen due to 
artifactual results from anti-CD95 antibodies (Huang et al. 1999). Data from these 
authors demonstrated that only a membrane bound aggregated CD95L consistently 
initiated apoptosis which was not reliably mimicked by anti-CD95 (Huang et al. 1999; 
Huang et al. 2000). This data was however challenged by Peter and co-workers who
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used a highly active triinerised form of CD95L to show the existence of type I and 
type II cells consistent with previous data using anti-CD95 antibody (Schmitz et al. 
1999; Barnhart et al. 2003). Therefore Type I/II cell systems do not seem to be 
dependent on the stimulus used and are generally accepted to be due to cellular 
characteristics.
1.2.1.4 Sensitisation to CD95-induced apoptosis
Cell lines can range from highly sensitive to resistant to death receptor-induced death 
when exposed to recombinant death ligands or antibodies (Gutierrez et al. 1999; 
Luschen et al. 2000; Kang et al. 2003). Those which show resistance to death 
receptor-induced death such as CD95 or TRAIL may be converted to a susceptible 
form by the co-addition o f metabolic inhibitors such as cycloheximide (CHX) or 
actinomycin D (ActD). Although sensitisation with these chemicals can be used on 
those cell lines expressing low levels o f death receptors, the treatment o f cells with 
CHX does not result in an increase in the expression o f CD95 (Gutierrez et al. 1999). 
Scaffidi et al. (1999) proposed that CHX sensitised cells by acting between caspase 8 
and the mitochondria, therefore only those cells dependent on the mitochondrial 
pathway (type II) would be affected by the addition of metabolic inhibitors. Fulda et 
al showed that CHX down regulates inhibitory proteins such as FLICE-like 
interleukin 1(3 converting enzyme inhibitory protein (FLIP), RIP and X linked 
inhibitor of apoptosis (XIAP) (Fulda et al. 2000). It was suggested that by down 
regulating these short lived inhibitory proteins CHX enhances caspase-8 activity 
resulting in sensitisation. Further evidence for an increase in caspase-8 activity by 
CHX was demonstrated by Kang and co-workers, who tested the apoptotic potential 
o f TRAIL in a range o f lymphocytic leukaemia cell lines. Their work showed
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different cell lines to be either sensitive to TRATL-induced apoptosis, convertible 
using CHX, or resistant. In those cells where CHX increased TRAIL-induced 
apoptosis, caspase-8 activity was shown to be increased (Kang et al. 2003).
It may therefore be hypothesised that the action o f CHX is to increase the activity of 
caspase-8, possibly by decreasing the expression o f those inhibitory proteins which 
would otherwise cause the cell to be resistant to apoptosis. Despite this some lines 
however remain completely resistant to death receptor-induced apoptosis which may 
be due to the loss o f another essential apoptotic protein such as Bax (Gutierrez et al. 
1999) or complete lack o f expression of a death receptor (Kang et al. 2003).
1.3 Necrosis
Necrosis is often described as ‘passive cell death’ and unlike apoptosis results in lysis 
of the cell and subsequent release of cell contents to surrounding tissues which may 
result in activation o f an inflammatory response (Proskuryakov et al. 2003). The 
morphology of a necrotic cell is veiy different from those o f apoptotic cells for 
example, where apoptotic cells maintain integrity o f the plasma membrane, necrotic 
cells loose this integrity resulting in release o f cytosolic components. Necrosis is 
usually associated with a lack o f caspase activation (see below) which is replaced by 
calpain activation. However in certain circumstances necrotic morphologies are 
associated with caspase activity (Niquet et al. 2003).
Necrosis has also been described not as a mechanism of cell death but as the 
pathology that occurs once the cell is dead (Kanduc et al. 2002). This ‘necrotic 
pathology’ is most relevant where cell death arises from a lack o f energy. For
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example following an ischaemic insult the centre of the damaged tissue suffers a 
profound energy loss resulting in cell death from which the morphology is described 
as necrotic. However, there is evidence to show that there are also ‘programmed’ 
necrotic pathways distinct to those observed during apoptosis supporting the idea that 
at least certain forms of necrosis are processes that actively contribute to the demise 
of the cell (Proskuryakov et al. 2003).
1.4 Autophagic Cell Death
Autophagy is not primarily a cell death system but a means for maintaining cellular 
homeostasis by contributing to the turnover o f cellular components. The term 
‘autophagy’ can be translated as ‘self-eating’ whereby cellular components are 
degraded by enzymes from within the cell. During this process parts of the cytoplasm 
and organelles are surrounded by a double membraned ‘autophagosome’, the presence 
of which is indicative o f the autophagic process. Once formed, the autophagosome 
fuses with lysosomes resulting in the degradation o f the autophagosome content 
(Yoshimori 2004). During instances of starvation autophagy is dramatically induced 
thereby maintaining an amino acid pool and the translation o f essential cellular 
proteins. Autophagic features have often been observed in dying cells (Kitanaka and 
Kuchino 1999; Edinger and Thompson 2004) as well as several human pathologies 
including Alzheimer’s disease (Mizushima et al. 2002). However, the presence of 
autophagic morphologies in dead/dying cells does not necessarily identify the 
autophagic process as the cause o f the disease; merely that it was present at the time 
of cell death.
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Recently Yu and co workers (Yu et al. 2004b) described what appeared to be an 
autophagic mediated form of cell death. In their system inhibition o f caspases 
(specifically caspase-8) induced cell death with features of autophagy. Furthermore, 
inhibitors of autophagic proteins could prevent this caspase inhibitor-induced cell 
death. This research suggests that this form o f cell death is dependent on the 
autophagic process, indicating a role for autophagy in cell death. A different link 
between autophagy and apoptosis was illustrated by Elmore and co-workers who 
described a model o f hepatocyte autophagy where upon nutrient withdrawal 
mitochondrial membranes were permeabilised (a feature commonly associated with 
apoptosis) and subsequently destroyed by autophagosomes (Elmore et al. 2001). 
These different findings from models o f autophagy and apoptosis support the idea o f a 
cell type and scenario dependence on the type o f cell death initiated.
Autophagic cell death is not usually associated with caspase activity. However, it has 
been shown that a human homologue of the Drosophila cell death gene HSpinl 
induces autophagic cell death in hepatocytes via association with anti-apoptotic 
proteins Bcl-2 and B c1-Xl (Yanagisawa et al. 2003) indicating the involvement of 
‘pro-apoptotic’ proteins.
1.5 Proteases as the Executioners of Cell Death
Whether the pathway of cell death followed is apoptotic, necrotic or autophagic, 
proteases are an essential feature. Breaking down cellular structures and inactivating 
anti-apoptotic proteins these enzymes and their activation have been widely studied in 
many cell systems.
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1.5.1 Caspases
Caspases are widely known as the major executioners o f apoptosis although their 
activation is not strictly limited to apoptosis and has been observed in necrosis or even 
cell survival (Bergeron et ak 1998; Kennedy et al. 1999; Benchoua et al. 2001). They 
form part o f a highly conserved group o f pathways, essential to the organised 
breakdown of the cell.
The role of caspases in apoptosis was first identified by studies using the nematode 
Caenorhabditis elegans leading to the discovery o f CED-3, which when mutated, 
abolished all programmed cell death within the nematode (Horvitz et al. 1983). 
Structural comparisons later showed that CED-3 is related to the mammalian gene 
interleukin-ip converting enzyme (ICE) (Yuan et al. 1993). ICE, also known as 
caspase-1, is involved in the activation and maturation of cytokines such as 
interleukin-ip and interferon-y inducing factor (IGIF) which is involved in 
inflammation (Cerretti et al. 1992; Thornberry et al. 1992). Further investigation into 
other mammalian homologues resulted in the discovery o f a family o f ‘killer 
proteases’ with highly conserved sequences (reviewed in Nicholson and Thornberry 
1997; Sadowski-Debbing et al. 2002).
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Figure 1,4 Phylogénie tree of vertebrate caspases.
A phylogénie tree showing the relationship o f vertebrate caspases based on amino 
acid sequence (Taken from Yabu et al. 2001).
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Knockout studies have highlighted important aspects o f caspase activit}' within 
mammalian systems (Sadowski-Debbing et al. 2002). Caspase-11 knockouts result in 
a lack of caspase-1 activation and the subsequent cytokine production associated with 
caspase-1 activity (Wang et al. 1998), indicating a hierarchy of caspase activation. 
Similarly, caspase-9 knockouts show a reduction in caspase-3 activity resulting in a 
similar pathology to that o f caspase-3 knockouts (Kuida et al. 1998). The dependency 
o f certain caspases to be activated by others led to the classification o f two groups of 
caspases. The initiator caspases such as caspases 1, 9 and 8 initiate caspase pathways 
by activating caspases fi'om the second group: the effector caspases. Effector 
caspases are those which directly contribute to the morphological features o f 
apoptosis such as DNA breakdown and cell blebbing (Zheng et al. 1998).
Caspases exist within healthy cells as inactive precursors or ‘zymogens’. In this ‘pro’ 
form they have no proteolytic activity and require activation via proteolytic cleavage. 
The pro-caspase is cleaved, removing the pro domain and forming a large and a small 
subunit which dimerise and along with one other caspase form an active 
heterotetramer (see Figure 1.5). The length o f the prodomain often confers the 
caspase’s activity as either an effector or initiator. Those with short pro domains such 
as 3, 6 and 7 are associated with effector activity whereas those with long pro­
domains, such as caspases 1 ,2 ,4 , 5, 8, 9 and 10, are initiator caspases (Cohen 1997).
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Figure 1.5: Pro-caspase cleavage and activation
Caspases exist within the cell as inactive monomers. Upon activation they are 
cleaved into large and small subunits, removing prodomain. Activity requires 
dimérisation o f two cleaved molecules to form a heterotetramer made up o f two large 
subunits and two small subunits.
Interestingly, loioclcout studies reveal a certain amount of tissue specificity among 
caspases. For example, caspase 2 knockouts seem to predominantly affect female 
germ cell development (Bergeron et al. 1998) and caspase 3 knockout mice show 
significant levels o f brain abnormality during development (Kuida et al. 1996). The 
study by Kuida and co-workers showed that despite a lack o f caspase-3 other cells 
were equally sensitive to apoptotic stimuli known to activate caspase-3. This 
indicates a certain level o f redundancy amongst the caspases. In this example 
caspase-3 may be replaced by other effector caspases such as 7 or 6 which also target 
the protein sequence DEVD. Quite why this redundancy is not present within the 
brain remains to be elucidated.
1.5.1.1 Caspase-3
Caspase-3 is one o f the major effector caspases and its activation is often associated 
with the ‘point o f no return’ within the apoptotic cascade. It can be activated via a 
number o f different pathways including that o f death receptor pathways and internal 
death signalling (Figure 1.6). Its targets include structural proteins gelsolin, a-fodrin 
and Lamin B (Zheng et al. 1998), the DNA damage sensing protein PARP (Nicholson 
et al. 1995) and the inhibitor o f caspase-activated DNase (ICAD) (Enari et al. 1998; 
W olf et al. 1999). Cleavage o f these targets contributes to some of the major 
morphological features o f apoptosis. For example, cleavage o f ICAD releases and 
activates caspase activated DNase (CAD) which results in DNA ftagmentation. 
Because o f the importance o f caspase-3 in apoptosis, the detection o f its activation is a 
good indicator o f apoptosis and the development of efficient methods for its detection 
allow swift identification o f apoptotic stimuli.
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Figure 1.6 Pathways of caspase-3 activation.
Upon binding o f the ligand to the death receptor, initiator caspases are recruited 
(caspase-8 or -10) which may directly cleave and activate caspase-3. Initiator 
caspases may also cleave Bid to form tBid which contributes to the permeabilisation 
o f the mitochondrial membrane by activating pro-apoptotic proteins such as Bax and 
Bak. Permeabilisation of the mitochondrial membrane results in loss o f cytochrome c 
which associates with APAF-1 and caspase-9 to form an apoptosome" which 
subsequently activates caspase-3 (Adapted from Zimmermann et al. 2001).
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1.5.2 Calpains
Calpains, like caspases, are executioners o f cell death. Their activation alone is most 
commonly associated with necrosis but is often associated with apoptosis alongside 
that o f caspase activity (Wang 2000). Calpains are calcium dependent cysteine 
proteases, occurring as inactive precursors requiring autolytic cleavage and Ca^ '*' for 
activation (Carafoli and Molinari 1998; Chan and Mattson 1999; Wang 2000). They 
are grouped into two categories; ubiquitously expressed calpains such as ji and m 
calpain (calpains 1 and 2) and those which are tissue specific such as calpain 3 which 
is specific to muscle (Carafoli and Molinari 1998).
Existing as inactive precursors, calpains may be activated by an influx of Ca^^, 
leading to an interaction of Ca^^ ions with the multiple binding sites on the calpain 
(see Figure 1.7). This produces a conformational change resulting in the activation o f 
the protease (Friedrich 2004). To ensure no untimely activation o f calpains, an 
endogenous inhibitor of calpains exists within cells: calpastatin. Calpastatin interacts 
with calpains via interaction with the calcium binding domains (Moldoveanu et al. 
2002; Tompa et al. 2002) and has shown to be cleaved by caspases during apoptosis 
(Porn-Ares et al. 1998). Recently, however a role has been put forward for calpastatin 
fiagments as calpain activators. Calpastatins contain four inhibitory domains, each 
containing three highly conserved repeats (subdomains) termed A, B and C. Upon 
analysis o f individual fiagments, it was found that region B alone is inhibitory 
whereas subdomains A and C, binding to the large and small subunits respectively 
(see Figure 1.7), actually activate calpains at a lower Ca'"  ^concentration (Takano et al. 
1995; Tompa et al. 2002). This activation o f calpains by fragments o f calpastatin
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would also go some way to explaining the unusually high Ca^^ concentrations 
required for calpain activation in vitro (Friedrich 2004).
The activation and target specificity o f calpains show many similarities to that of 
effector caspases such as caspase 3. For example, both require proteol}4ic activation 
and once active show a similarity in target specificity, both calpains and caspase-3 
targeting a ll spectrin, actin and PARP (Wang 2000). Despite the similar target sites, 
caspase and calpain activity can be identified separately as calpain cleavage often 
results in larger protein fragments. For example, Figure 1.8 illustrates a typical fodrin 
western blot isolating calpain and caspase cleaved fragments (Chan and Mattson 
1999; Wang 2000).
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Figure 1.7 General structure of dimeric calpains in relation to their function.
The most predominant calpains (calpains p and m) are associated with a smaller 
regulatory calpain subunit. Interaction is via a homodimerisation with one of the EF 
hands in domains IV and VI. The remaining 4 EF hands act as calcium binding 
motifs. Domains 1 and V are cleaved during calpain activation, the protease activity 
o f which is derived from domain 11 (Huang and Wang 2001).
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Despite their classic role as degenerative enzymes, a physiological role for calpains 
may lie in cell division and plasticity. For example during cell division significant 
alterations o f the cytoskeleton are required which, as targets of calpains, would 
explain observed calpain activation during cell division (Carafoli and Molinari 1998; 
Raynaud et al. 2004). Furthermore, due to the complex structures o f cells within the 
nervous system, calpain activation may play a role in modulating neuronal synaptic 
plasticity (Chan and Mattson 1999). However a large amount o f evidence has 
indicated that one of the major roles o f calpains is degenerative (see below).
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Figure 1.8 The differences in fodrin cleavage between calpains and caspases.
In the absence o f caspase-3 activity fodrin cleavage is produced from calpain activity 
resulting in bands at 145 and 150kDa which can be identified by western blotting. In 
the presence o f caspase-3, a band at 120kDa is also present (Taken from Wang 2000). 
The largest fragment present in all samples is due to the total level o f uncleaved 
fodrin.
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1.5.3 Cathepsins
Cathepsins are a third group o f proteases that are associated with cellular degradation 
(Fehrenbacher and Jaattela 2005). They are grouped according to their active site 
amino acid, the majority o f cathepsins are cysteine proteases (B, C, H, F, K, L, O, S, 
V, W, and X/Z) but others may be aspartate (D and E) or serine (G) cathepsins. Their 
targets are cellular proteins and organelles during either autophagic or heterophagic 
(from other cells) degradation. However, cathepsin B has been shown to 
proteolytically activate caspase-11 (Schotte et al. 1998) and the appearance of 
cathepsin B on the cell surface is also associated with metastasis and tumour 
invasiveness (Sloane et al. 2005).
The release o f cathepsins such as cathepsin B into the cytosol has been shown to 
induce programmed cell death (Broker et al. 2005). Furthermore, extracellular 
cathepsin B released from microglia have shown to be toxic to a neuronal cell line as 
well as primary cerebellar granule neurons (Kingham and Pocock 2001). Cathepsins 
have also been associated with sensitisation to TNFa in certain cell lines, indeed 
cathepsin B knockouts show resistance to TNFa-induced cell death in mice 
hepatocytes (Guicciardi et al. 2001).
1.5.4 Pharmacological Inhibition of Proteases
Many small peptide inhibitors are currently available for the study o f proteases such 
as calpains and caspases. Most o f these inhibitors are based on the specific cleavage 
sequence o f the protease. For example inhibitors targeting caspase-3 and related 
caspases use the sequence DEVD as the target site linked to an inhibitory motif.
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Inhibitory motifs include fluoro and chloro methyl ketones (FMK/CMK) which act as 
irreversible inhibitors, or aldehyde groups (CHO) which acts as reversible inhibitors.
In a study using the caspase inhibitor z-DEVD-FMK, neuronal degeneration caused 
by traumatic brain injury was reduced indicating a role for caspases, predominantly 
caspase-3. However control brains observed no cleavage o f caspase-3 or its substrate 
PARP which implied a non-specific effect o f z-DEVD-FMK. Further investigation 
into z-DEVD-FMK treated brains observed a reduced expression o f calpain I and 
calpain mediated a-spectrin cleavage were reduced suggesting that z-DEVD-FMK 
may also inhibit calpains (Knoblach et al. 2004), Methyl ketone linked caspase 
inhibitors have also been shown to inhibit cathepsins at concentrations previously 
thought to inhibit caspases (Schotte et al. 1999) In this study both broad spectrum 
caspase inhibitors (z-VAD-FMK and y-VAD-CMK) and the more selective caspase- 
3/9 inhibitor z-DEVD-FMK were observed to inhibit caspases and calpains. The 
negative control caspase inhibitor z-FA-FMK is sometimes used alongside caspase 
inhibitors shown to inhibit calpains and cathepsins as z-FA-FMK has been shown to 
inhibit calpains and cathepsins but not caspases (Guo et al. 1998).
In some cases, an unusual effect o f the broad spectrum caspase inhibitor z-VAD-FMK 
is to sensitise cells, actually enhancing cell death. For example in a caspase- 
independent system, inhibition of caspases has no affect on cell death so, a caspase 
inhibitor which enhances cell death suggests that caspases (or other targets o f z-VAD- 
FMK) are actually limiting cell death. In a study by Vercammen and co-workers, 
TNFa-induced cell death was enhanced by the addition of the caspase inhibitors z- 
VAD-FMK and the Cowpox caspase inhibitor CrmA (Vercammen et al. 1998). The
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enhancing effect of z-VAD on TNFa-induced cell killing was seen in a number of cell 
lines including fibrosarcoma NIH3T3 (Luschen et al. 2000) and L292 cell lines 
(Vercammen et al. 1998) and human neutrophils (Liu et al. 2003). This TNFa/z- 
VAD-fmk mediated cell death appears to be mediated by increased oxidant 
production (Liu et al. 2003) inhibition o f which limits TNFa/z-VAD-fmk mediated 
cell death (Vercammen et al. 1998), Morphologically the cell death induced by z- 
VAD-fmk showed signs o f both an apoptotic and necrotic morphology with nuclear 
condensation fragmentation but sometimes within the same cells nuclear and cellular 
swelling (Liu et al. 2003). Replication o f this data was not observed in other cell 
types (HeLa) which would suggest that this observation is cell type specific 
(Vercammen et al. 1998).
1.6 Mitochondria as Mediators of Cell Death
Mitochondria are key players in apoptotic pathways, with certain death stimuli 
actually requiring their participation to cause cell death (Scaffidi et al. 1998). In 
healthy cells the main role o f mitochondrial is to produce ATP by a process involving 
the electron transport chain (see Figure 1.9). Required for this generation is the 
presence of a membrane potential between the inner matrix and the intermembrane 
space. During certain types o f cell death, classically apoptosis, this membrane 
potential is lost due to the loss o f cytochrome c and subsequent cleavage o f complex I 
by active caspase-3 (Ricci et al. 2004).
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Figure 1.9 The mitochondrial electron transport chain
A simplified version o f the mitochondrial electron transport chain, showing the 
transportation o f electrons (e‘) fi'om complex I through to III from which cytochrome 
c (c) passes electrons to complex IV. Upon passing through complex IV, electrons 
combine with molecular oxygen (O2) and protons (H^) to form water. A 
mitochondrial membrane potential is formed by pumping protons from the inner 
matrix to the intermembrane space by complexes I, III and IV. ADP is converted to 
ATP as protons travel through complex V, from a high to a low (Adapted 
from Ricci et al. 2003)
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1.6.1 Cytochrome C
Cytochrome c forms an integral part o f the electron transport chain, residing within 
the mitochondrial intermembrane space and responsible for transporting electrons 
from the complex III (b-cl complex) to complex IV (c)Tochrome oxidase complex) 
(see Figure 1.9). Following certain apoptotic stimuli, including uv radiation and death 
receptor stimulation, the mitochondrial membrane is permeabilised resulting in the 
release o f mitochondrial proteins including cytochrome c and smac/DIABLO 
(SrinivasLila et al. 2001; Waterhouse et al. 2001 ; Waterhouse et al. 2002).
In the cytosol, cytochrome c forms part of the “apoptosome” (see Figure 1.6) along 
with Apaf-1 and pro-caspase-9. The formation o f this molecule results in the 
activation o f caspase-9 which is then able to dissociate and activate caspase-3 (Zou et 
al. 1999). Speculation has been made as to the extent of cytochrome c release; 
whether there is a threshold level required for the activation of downstream apoptotic 
events or whether it is an ‘all or nothing’ phenomenon. Green and co-workers used 
single cell analysis to show that c)4ochrome c release was in fact complete following 
a range o f stimuli (Goldstein et al. 2000). Following a complete loss o f cytochrome c 
from the mitochondria some detrimental effects might be expected to the electron 
transport chain and therefore energy production within the cell. However, release into 
the cytosol does not necessarily mean that the mitochondrial membrane potential 
(Aq/m) is lost. Indeed Green and co-workers showed that by inhibiting active 
caspases following cytochrome c release A\|/m can be maintained via what is thought 
to be a diffuse interaction between cytosolic cytochrome c and complexes III and IV 
(Goldstein et al. 2000; Waterhouse et al. 2001). This data indicates that loss of Avj/m 
is due to caspase-3 activity and not the loss o f mitochondrial proteins which was
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confirmed by further results from Ricci and co-workers who demonstrated caspase-3 
cleavage o f complex I (Ricci et al. 2003; Ricci et al. 2004).
1.6.2 Mitochondrial Permeability Transition Pore
Another theory as to the involvement o f pro-apoptotic factors such as Bax and Bak is 
the formation o f a larger complex known as the mitochondrial permeability transition 
pore (MPTP). Other molecules associated with the MPTP include the adenine 
nucleotide translocator (ANT), the voltage-dependent anion channel (VDAC) and the 
peripheral benzodiazepine receptor (PBR) which form part o f a ‘megachanneP (Narita 
et al. 1998; Scorrano and Korsmeyer 2003). Further evidence for the formation and 
dependence o f the MPTP on cytochrome c release has been shown via inhibitors of 
various co-factors associated with the MPTP. These include cyclosporine A, a 
regulator o f the pore complex, and Bonkrekic acid a direct inhibitor o f ANT (Narita et 
al. 1998; Zamzami et al. 2000).
1.7 Bcl-2 proteins
BH domain containing proteins are a group o f proteins affecting apoptosis in a 
positive or negative way. As a result these proteins have been grouped into either 
pro- or anti-apoptotic proteins (see Figure 1.10). Their involvement however, has not 
just been linked to apoptotic cell death but also autophagic cell death (Yanagisawa et 
al. 2003). The majority o f pro-apoptotic proteins contain the BH3 domain but their 
pro/anti-apoptotic nature is defined by the lack/presence o f a BH4 domain 
respectively (Figure 1.10).
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1.7.1 Anti-apoptotic: Bcl-2
The Bcl-2 protein was initially discovered in B cell lymphomas as part of a 
chromosome translocation that increased Bcl-2 expression and B cell proliferation 
(Tsujimoto et al. 1984). The action of Bcl-2 is associated with internal cellular 
membranes such as the mitochondrial, endoplasmic reticulum (ER) and nuclear 
membranes where it is thought to interact with pro-apoptotic molecules such as Bax 
and Bak, preventing them from acting on the mitochondria (Daniel et al. 2003). The 
major protective role o f Bcl-2 and other anti-apoptotic proteins is thought to be via 
inhibition of cytochrome c release, indeed Bcl-2 overexpression in cytochrome c 
mediated systems inhibits cell death (Jaattela et al. 1995). There is still some debate 
about the site o f action o f Bcl-2 proteins; whether their action is at the site o f the pro- 
apoptotic Bcl-2 proteins (such as Bax), direct action on the mitochondrial membrane 
or possibly an inhibition o f BH3 only proteins such as Bid (Daniel et al. 2003). 
However, there is convincing data showing the actions o f anti-apoptotic Bcl-2 
proteins are upstream o f the mitochondria as in cell free mitochondrial extracts 
recombinant B c1-X l was able to inhibit cytochrome c release but failed to inhibit 
caspase activation when exogenous c>4ochrome c was added to cytosolic extracts 
(Newmeyer et al. 2000).
Bcl-2 may also prevent certain types o f necrotic/oxidative forms o f cell death due to 
its antioxidant properties. Overexpression in a model o f oxidative stress partially 
prevented cell death via a reduction in reactive oxygen species (ROS) (Kane et al. 
1993). Furthermore Bcl-2 expression within the endoplasmic reticulum (ER) has 
shown to inhibit (Bax mediated) Ca"^ release (McConkey and Nutt 2001). This 
suggests another inhibitory function o f Bcl-2 which may explain its inhibition of some
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cell death systems which are thought to be regulated by excessive Ca^^ influxes such 
as neuronal stroke damage (Zhao et al. 2003).
1.7.2 Pro apoptotic: Bax
Bax, along with Bak, is a BH3 (Bcl-2 homology-3) domain-containing proapoptotic 
molecule. In vivo Bax is mainly observed to be cjTosolic but is associated with 
mitochondrial membranes during apoptosis. However, in many cell lines Bax has 
been observed to be continually associated with mitochondrial membranes in healthy 
cells (Antonsson 2001; Degli Esposti and Dive 2003). The pro-apoptotic actions of 
Bax require two essential steps. Firstly a conformational change resulting the 
exposure o f the N-terminal domain (Desagher et al. 1999) and secondly association 
with the mitochondrial membrane. Mutation studies with Bax have shown that the 
conformational change in Bax cannot affect apoptosis if Bax is unable to interact with 
the mitochondrial membrane (Nechushtan et al. 1999), also the conformational 
change is a reversible event and does not necessarily led to the completion of 
apoptosis (Makin et al. 2001). More recently HSpinl has been identified in humans 
and is thought to act in a similar way to Bax and Bak. In cells treated with TNFa + 
CHX, the conformationally active form of HSpinl was observed and localised at the 
mitochondrial with Bcl-2 and B c 1-X -l (Yanagisawa et al. 2003).
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Figure 1.10 Bcl-2 proteins and their structures
A simplified representation of apoptotic and anti-apoptotic Bcl-2 proteins and their 
domains. All contain BH3 domains but only those with BH4 domains are anti- 
apoptotic (Taken from Burlacu 2003). TM = transmembrane domain.
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The specific action o f Bax and its ability to induce cytochrome c release is still being 
questioned. Whether Bax or Bak or Bax-Bak oligomers alone can form pores 
sufficient for cytochrome c release or whether they are required as part of a larger 
pore complex has not yet been fully elucidated (Scorrano and Korsmeyer 2003). In 
either case the presence of one or both of the BH3 containing proteins (Bax or Bak) 
are required. In the absence o f both Bax or Bak the mitochondrial permeability is 
inhibited, but the absence o f either one is not enough to inhibit cytochrome c release 
(Degenliardt et al. 2002). Convincing data as to the importance o f Bax in cytochrome 
c release has been shown in cell free systems where mitochondria exposed to 
recombinant Bax show release o f cytochrome c (Jurgensmeier et al. 1998).
1.8 MAP Kinases
MAP Kinases (mitogen activated protein kinases) have been implicated in both 
apoptotic and necrotic forms of cell death. They are activated via a tier based system 
where map kinase kinase kinases (MAPKKKs), such as Ras and Raf, activate 
downstream MAP kinase kinases (MAPKKs), such as MEK 1/2 and MKK 4/7, which 
finally activate MAP kinases such as extracellular related kinase 1/2 (ERK 1/2) and 
jun-N terminal amino kinase (JNK). Their roles are known to extend from control of 
cell growth to cell death however, the precise pathways involved are not completely 
elucidated (Chang and Karin 2001). As suggested by the upstream activators MAPKs 
are activated by kinases and conversely can be inhibited by MAP kinase phosphatases 
(MKP) (Kamata et al. 2005).
Stress activated protein kinases which include Jun N-terminal amino kinase (JNK) 
and p38 are often associated with cell stress such as cold shock, hyperosmolarity and
ultraviolet (UV) irradiation (Yujiri et al. 1998). JNK targets proteins including p53 
(Yin et al. 2004) and c-jun (Waetzig and Herdegen 2004). Phosphorylation of p53 
acts to stabilise this protein which is then able to induce apoptosis. One way activated 
JNK is thought interact with the mitochondrial pathway is through interaction with 
phosphorylated BimL (Okuno et al. 2004). The transcription factor c-jun has been 
shown to induce activation o f apoptotic genes such as CD95 and CD95L (Martin- 
Villalba et al. 1999).
The apoptotic/necrosis inducer TNFa induces JNK activity (Xia et al. 2000; Sakon et 
al. 2003) and activation of the JNK pathway can result in increased FasL and or Fas 
expression (Kuan et al. 2003; Minogue et al. 2003). The involvement o f JNK activity 
in certain forms o f TNFa-induced cell death is thought to occur via ROS mediated 
inhibition o f JNK phosphatases which are particularly susceptible to oxidation 
(Kamata et al. 2005). The upstream activator o f JNK, MEKK 1 (a MAP KKK) has 
also been involved in caspase enhancement and apoptosis. Once cleaved by 
DEVDases such as caspase-3, a 91kD product is formed which is able to amplify 
caspase activity. However the full length 196kD MEKK 1 protein is unable to 
activate either caspases or apoptosis (Yujiri et ai. 1998). A downstream target of 
JNK, c-jun, has shown to block p53-induced growth arrest and constitutive expression 
results in p53 mediated apoptosis (Shaulian et al. 2000).
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Figure 1.11 MAP kinase pathways linked to their cellular effects.
MAP kinase pathways can be loosely grouped into growth related kinases such as 
ERIC, activated by upstream growth factors and stress associated kinases such as JNK 
and p38 which are upregulated following stress. However, overlap between these two 
pathways has been observed where in some systems ERK appears to link to apoptosis 
(Satoh et al. 2000; Stanciu et al. 2000) and JNK may mediate cell cycle progression in 
certain systems (Du et al. 2004).
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More recently kinases which have previously been associated with cell growth and 
proliferation have been implicated in cell death. ERK activity is upregulated 
following glutamate toxicity in a hippocampal cell line (Stanciu et al. 2000; Levinthal 
and Defranco 2004) and appears to be required for toxicity (Satoh et al. 2000). This 
would suggest that ERK and related kinases, previously thought to regulate cell 
proliferation, also play a role in cell death.
1.9 Reactive Oxygen Species
Within a normal cell it is thought that up to 1% of mitochondrial electron flow 
contributes directly to the formation o f superoxide radicals (Of") (Klein and 
Ackerman 2003). Normally, this low level ROS production is dealt with by enzymes 
such as superoxide dismutase (SOD), a mitochondrial enzyme which converts oxide 
radicals into hydrogen peroxide (H2O2) and molecular oxygen (O2) from which the 
peroxide is converted via glutathione peroxidase or catalase to non-harm All 
substances (see Figure 1,12). In the presence o f excessive ROS, intracellular 
structures such as mitochondria, DNA, lipids and proteins can be oxidised and 
damaged (Edwards et al. 1998; Fiers et al. 1999) resulting in disruption o f normal 
cellular processes and subsequent cell breakdown and death.
Interference with the mitochondrial electron transport chain is thought to contribute to 
excessive ROS production. TNF-a has been shown to induce cell death via increased 
mitochondrial ROS production. It is thought that TNF-a induced interference 
between complexes I/II and III results in an increased number of electrons 
contributing to ROS formation. Indeed, inhibition of complexes I and/or II 
significantly reduces cell death (Fiers et al. 1999). Excessive ROS production has
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also been attributed to phospholipid degeneration and has been proposed as a 
mechanism of neurodegeneration (Adibliatla and Hatcher 2003). Phospholipids are 
degraded by enzymes including phospholipase A] (PLA]), an enzyme thought to be 
upregulated in the hippocampus following ischaemic injury (Arai et al. 2001). Upon 
activation of PLA2, free fatty acids are hydrolysed resulting in the formation of 
arachidonic acid, which when metabolised results in free radical production. 
Attenuation o f PLAj stimulation decreased fi*ee radical production and significantly 
inhibited cell death following ischaemia (Adibhatla and Hatcher 2003).
As well as causing irreversible damage to the cell, ROS are able to activate apoptotic 
pathways leading to cell death. One mechanism by which ROS are able to induce 
apoptosis is by dimérisation and therefore activation of apoptosis signalling kinase-1 
(ASKl) (Gotoh and Cooper 1998). ASK I is a MAPKKK (see Figure 1.11) capable of 
inducing apoptosis via FNK and p38 pathways (Ichijo et al. 1997). In a later study it 
was also shown that ROS enhance sustained JNK activation via oxidation and 
inhibition of upstream MAP kinase phosphatases (Kamata et al. 2005). ROS have 
also been shown to induce apoptosis via direct activation o f caspase-9 (Kim and Park 
2003). Upon ROS mediated caspase-9 activity downstieam apoptotic events are then 
initiated including cytochrome c release.
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Figure 1.12 Ântioxidaiit enzymes and their reactions.
Reactive oxygen species such as oxygen radicals (O2'") are able to be converted to 
molecular oxygen and hydrogen peroxide (H2O2) via superoxide dismutase (SOD). 
Hydrogen peroxide, a potent oxidant, can then be broken down via catalases, found 
only in peroxisomes, or glutathione peroxidase, found in the cytosol and 
mitochondria. Wliereas peroxisome based catalase breakdown of hydrogen peroxide 
only requires two peroxide molecules, glutathione peroxidase breakdown requires two 
reduced glutathione (GSH) molecules in order to convert peroxide into water (H2O) 
and glutathione disulphide (GSSG) (Forman and Torres 2002).
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1.10 Neurodegenerative Pathologies
Neurodegenerative pathologies include Alzheimer’s disease, Parkinson’s disease, 
traumatic brain injury and cerebral ischaemia. All o f these are characterised by the 
loss o f neurones and investigations into the molecular pathways involved in this 
degeneration aim towards identifying an inhibitory mechanism to limit the damage 
associated with these diseases. This investigation has focussed on the biochemical 
and molecular pathways associated with ischaemic damage and although there is 
thought to be some overlap between these disorders this introduction will focus 
mainly on brain ischaemia.
1.11 Brain Ischaemia
Ischaemia is characterised by a loss o f oxygen and glucose for example via loss of 
circulation preventing blood flow to the brain. Following the deprivation of oxygen 
and glucose to regions of the brain significant levels o f both apoptotic and necrotic 
death are observed as shown in animal models via middle cerebral artery occlusion 
(MCAO) resulting in part or all o f the brain being deprived o f blood supply 
(Benchoua et al. 2001; Northington et al. 2001). The resulting infarct region consists 
of a necrotic core where oxygen and glucose levels are at their lowest. The outer or 
penumbral region o f the infarct maintains low levels o f oxygen perflision, due to 
surrounding blood vessels and capillaries, and has been proposed to be the region 
which can be rescued by pharmacological intervention (Yao et al. 2001). Furthermore 
it has been proposed that, following an ischaemic insult all affected cells will initiate 
steps towards apoptosis. However, it is only those in the hypoxic penumbral region 
which maintain the low levels o f oxygen may be able to commit through to the final 
stages (Nicotera et al. 1999; Benchoua et al. 2001).
41
The main damage occurring immediately after an ischaemic insult is thought to be 
necrotic, as a direct result o f excessive neurotransmitter release such as L-glutamate 
where levels of extracellular glutamate can rise from 0.6mM to 360mM (Bouvier et 
al. 1992). However, in 1982, results from Pulsinelli and Kirino described a delayed 
neuronal damage following ischaemic injuries in the rat (Pulsinelli et al. 1982) and 
gerbil (Kirino 1982) hippocampus. This damage occurred between 24 and 72 hours 
post ischaemia, in tissue which had appeared healthy 30 minutes post ischaemia. 
More recently this data was confirmed in another model o f rat ischaemia where it was 
shown that up to 1 0 % of ischaemic hippocampal neurones resulted in an apoptotic 
morphology including features such as caspase-3 activation and chromatin 
condensation (Muller et al. 2004). This data suggests a biphasic means o f damage; an 
initial necrotic death followed by a delayed apoptotic death.
1.11.1 CD95 Mediated Stroke Damage
It is generally accepted that a major cause of cell death following cerebral ischaemia 
is due to excitotoxicity whereby excessive (high micromolar) neurotransmitter release 
results in large calcium influxes and ultimately cell death (Hou and MacManus 2002). 
However, recent data also implicate a death receptor mediated mechanism of cell loss 
following ischaemia. This data included an increase in active caspases associated 
with the CD95 receptor following ischaemia (Namura et al. 1998; Benchoua et al. 
2001; Gibson et al. 2001; Northington et al. 2001; Jover et al. 2002; Kuan et al. 2003; 
Shin et al. 2004) and increases in the expression o f the CD95 receptor following 
ischaemic insults to the brain (Felderhoff-Mueser et al. 2000; Gibson et al. 2001; Jin 
et al. 2001; Northington et al. 2001; Kuan et al. 2003). Indeed, mice expressing a
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mutant form of the Fas receptor (Ipr), or mice injected with a CD95 ligand (CD95L) 
neutralising antibody, are reported to show a reduced infarct volume following 
cerebral ischaemia (Rosenbaum et al. 2000; Martin-Villalba et al. 2001). Therefore in 
order to successfully develop a complete therapeutic treatment strategy for stroke, the 
characterisation o f CD95-induced neuronal cell death is of significant interest.
1.11.2 L-Glutamate-Induced stroke damage
Following a brain ischaemic insult to the brain large amounts o f neurotransmitters are 
released including L-glutamate where concentrations can increase up to 500 fold 
(Bouvier et al. 1992; Hoy te et al. 2004). It is thought that much o f the resulting 
damage is due to overstimulation o f glutamate receptors in the surrounding cells. 
This overstimulation leads to a sustained influx o f calcium ions (Ca^ "^ ) resulting in cell 
death via what is thought to be a mixture o f apoptotic and necrotic mechanisms (Lee 
et al. 1999; Sattler and Tymianski 2001). As a result of this evidence a number o f 
glutamate receptor antagonists have been developed in order to block this sustained 
receptor activation. However when these antagonists were taken into clinical trials 
this no significant benefits were observed (Davis et al. 1997; Calabresi et al. 2003; 
Hoy te et al. 2004). The lack of success in these clinical trials has been described as 
due to badly designed animal models where survival following an ischaemic insult 
was measured within the initial 48 hours which may only reflect a delay in ischaemic 
damage. Furthermore, the antagonists may also have affected healthy neurones 
therefore exacerbating neurotoxicity (Ho)4:e et al. 2004).
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The lack o f success with glutamate receptor antagonists led to investigation into 
alternative routes o f glutamate toxicity (Greene and Greenamyre 1995; Gwag et al. 
1995; Suzuki et al. 2003). In 1989, Murphy et al. demonstrated that high levels of 
extracellular glutamate (1-lOniM) competed with cystine uptake via a 
cystine/glutamate antiporter (Murphy et al. 1989). Under normal conditions this 
antiporter flmctions to passively transport cystine into the cell for the exchange of 
glutamate in a 1:1 ratio (see Figure 1.13) (Bannai 1986; Sato et al. 1999). Once inside 
the cell cystine is reduced to cysteine which is converted into glutathione, required by 
the cell for its antioxidant properties (see Figure 1.12). However following excessive 
glutamate exposure this antiporter is inhibited thus reducing cystine uptake. The 
subsequent reduction in glutathione production results in the cell being susceptible to 
reactive oxygen species (ROS) damage and cell death via an oxidative stress mediated 
mechanism (Tan et al. 1998b; Tan et al. 2001).
Superoxide ROS can be produced by the mitochondria by complexes I and III. The 
superoxides produced are usually short lived and converted via SOD to another potent 
ROS; H2O2 (Starkov et al. 2004). Although H2O2 can be broken down by catalase, it 
is glutathione peroxidase which is more common throughout the cell and responsible 
o f the majority o f H2O2 breakdown (Forman and Torres 2002). ROS target many 
cellular structures including lipids, proteins and DNA and have been hypothesised to 
contribute to increases in neuronal apoptosis associated with aging (Edwards et al. 
1998) and more recently neurodegenerative pathologies including ischaemia and 
Alzheimer’s disease (Adibhatla and Hatcher 2003; Klein and Ackerman 2003; 
Starkov et al. 2004; Pereira et al. 2005).
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Figure 1.13 The glutamate/cystine antiporter.
Extracellular cysteine is oxidised to cystine which is taken up into the cell passively 
via an anti porter resulting the exchange o f glutamate for cystine. Within the cell 
cystine is reduced to form cysteine which is converted into glutathione.
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1.11.2.2 Oxidative L- Glutamate Toxicit)>: Apoptosis or Necrosis ?
In an early study o f oxidative glutamate toxicity Ratan et al (1994a) demonstrated that 
homocysteate (a glutamate analogue) induced chromatin condensation and 2 0 0 bp 
DNA fragmentation indicative o f apoptosis. Furthermore these features were 
inhibited by not only antioxidants but the macromolecular synthesis inhibitor 
cycloheximide. Together with the Icnowledge that protein synthesis inhibitors have 
previously been shown to inhibit apoptotic cell death, this study described the cell 
death as apoptotic.
Upon further investigation it was demonstrated that the protection afforded by 
cycloheximide may have been due to an indirect affect whereby the inhibition of 
protein synthesis allowed more o f the intracellular pool of cysteine to be converted to 
glutathione thus resulting in protection (see Figure 1.14) (Ratan et al. 1994b). This 
model o f CHX protection from oxidative glutamate toxicit}' was directly opposed by 
Tan et al (1998a) whose work indicated that CHX protected against oxidative 
glutamate toxicity via blocking the synthesis o f apoptotic proteins. Although 
differences between the two studies may be attributed to the different models used, 
one theory does not necessarily exclude the other and a combination o f increased 
glutathione production and a reduction in pro-death proteins may be possible.
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Figure 1.14 Proposed model of CHX protection against glutamate-induced 
oxidative stress.
Upon reduction o f cystine uptake via increased extracellular glutamate, intracellular 
cysteine is depleted as available stores are taken up in protein synthesis. However, in 
the presence o f protein synthesis inhibitors such as cycloheximide. the available 
cysteine is converted to glutathione thus maintaining normal levels o f glutathione and 
offering protection from oxidative damage (adapted from Ratan et al. 1994b).
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Electron microscopy images following oxidative glutamate toxicity by Tan et al 
(1998a) did not show indicate chromatin condensation, unlike data found from 
chromatin staining in the previous study (Ratan et al. 1994a). This apparent 
contradiction may however reflect an unusual form of chromatin condensation 
whereby observed chromatin condensation from nuclear staining is not reflected by 
electron microscopy. A similar form of chromatin condensation was identified by 
Bezvenyuk et al (2003) where although Hoechst staining indicated nuclear 
condensation, electron microscopy images did not reflect the classic condensation and 
fragmentation normally associated with apoptosis (see Figure 1.1 and Figure 1.15).
Investigations into the role of caspases and oxidative glutamate toxicity have 
produced varied results. Broad caspase inhibition was initially found to inhibit 
oxidative glutamate toxicity (Tan et al. 1998a), whereas later studies found no 
protection (van Leyen et al. 2005). Both groups however found no inhibition o f cell 
death by inhibiting caspase-3. The differences in broad caspase inhibition may be due 
to differences in the cell death assays used. Van Leyen et al used the LDH assay 
which measures lactate dehydrogenase (LDH) release from compromised membranes 
and Tan et al used the 3-(4,5-dimethyIthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay which measures the activity o f a mitochondrial enzyme. Differences in 
inhibition studies between these two assays used have been noted previously and it 
has been suggested that when investigating inhibition assays, the LDH assay often 
provides more accurate results (Lobner 2000).
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BFigure 1.15 Comparison of chromatin condensation in electron chromatin 
images and nuclear stains.
Nuclear staining by Hoechst (A & C) does not necessarily reflect classic chromatin 
condensation and fragmentation associated with ‘apoptosis' as illustrated by electron 
micrograph images (B & D). Untreated neurones stained with Hoechst compared to 
the same samples analysed by electron microscopy (B) show diffuse nuclear 
structures. Glutamate treated neurones showing chromatin condensation with 
Hoechst staining (C) not however detected with electron microscopy, or 
fragmentation (D). Images taken from Bezvenyuk et al (2003).
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The role o f the pro-apoptotic molecule Bax was also investigated in primary models 
o f oxidative glutamate toxicity. However, Bax knockouts failed to alter oxidative 
glutamate toxicity indicating a Bax mediated pathway is not involved in oxidative 
glutamate toxicity (Dargusch et al. 2001). Despite this, a small protective affect was 
afforded by Bcl-2 overexpression however, this was mainly attributable to its 
antioxidant properties (Howard et al. 2002).
From the evidence based above it is hard then to draw solid conclusions on the exact 
mechanism dominating oxidative glutamate toxicity. It is clear that the mechanism 
will not fit into a clear ‘apoptotic’ or ‘necrotic’ phenoty^pe, indeed it has been 
described as a novel form o f cell death ‘oxytosis’ (Tan et al. 2001). However, before 
firm conclusions can be drawn many o f the discrepancies between different groups 
and different model systems must first be resolved.
1.11.3 The Role of Caspases in Brain Ischaemia
As discussed above, the involvement of caspases in brain ischaemia would indicate a 
role for apoptosis. As apoptosis is an energy requiring process, and the penumbra has 
already been identified as the site o f apoptotic cell death, then caspase inhibitors may 
be able to limit the damage in this area following ischaemic damage. Studies using 
caspase inhibitors in vivo have shown success in limiting the apoptotic cell death 
associated with cerebral ischaemia (Gottron et al. 1997; Gil lardon et al. 1999). A 
further advantage of this pharmaceutical application is that caspase activation (and 
associated apoptotic cell death) is delayed following the injury and therefore this 
offers a window of opportunity where even after the ischaemic insult, 
pharmacological intervention can be applied (Fink et al. 1998). The problem however
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with caspase inhibition is when the ischaemic insult does not result in a penumbral 
area, such as after global ischaemia. Studies in rats looking comparing focal and 
global insults have shown that caspase inhibitors, although effective against focal 
insults are unable to limit the injury following global ischaemia (Li et al. 2000).
1.11.4 The Role of Calpains in Brain Ischaemia
The role o f calpains in neurodegeneration has previously been described in both 
ischaemic and Alzheimer models (Huang and Wang 2001; Veeranna et al. 2004). As 
described above, excitotoxic insults (such those following ischaemia) increase 
intracellular Ca“'*' which may subsequently activate calpains (Carafoli 2004). The 
endogenous calpain inhibitor calpastatin has limited therapeutic potential as it is 
membrane impermeable. However, there a number of other available calpain 
inhibitors which have had some success in vitro as neuroprotectants. In a model o f 
focal cerebral ischaemia in rats, the calpain inhibitor MDL 28,170 inhibited cell death 
within a six hour window of protection (Markgraf et al. 1998). P I50606 interacts 
with the calcium binding domains o f calpains. In a cell model o f ischaemia 
PD150606 was also able to limit cell death (Wang et al. 1996). Evidence for the role 
o f calpains has been observed in in vivo models of neuronal injury where calpain 
inhibitors limit neuronal damage following traumatic brain injury (Kupina et al. 2001; 
Knoblach et al. 2004). Furthermore calpain mediated cleavage o f a-fodrin (see 
Figure 1.8) was observed in protein samples from the rat brain following injury (Pike 
et al. 1998),
The inactivation of protein kinase C (PKC) via calpain cleavage has been implicated 
in ischaemic injury. In an in vivo model o f ischaemic injury calpain inhibition limited
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PKC breakdown and limited cell death (Harada et al. 1999). Furthermore, in a model 
o f glutamate-induced ischaemic injury, activation of PKC provided neuroprotection 
(Davis and Maher 1994) and has also been shown to provide protection from death 
receptor mediated systems (Scaffidi et al. 1999). Therefore some o f the calpain 
mediated toxicity following cerebral ischaemia may be due to its ability to cleave and 
inactivate PKC.
Interestingly, NMDA receptors are targets o f calpains, the cleavage o f which would 
reduce calcium intake therefore protecting the cell from excitotoxic damage (Bi et al. 
1998). Furthermore, calpains have been shown to inactivate caspases by cleaving 
them into inactive fragments (Chua et al. 2000). Together this data suggests a 
possible protective mechanism for calpains under certain circumstances. However, it 
is clear that over activation o f these proteases contributes to cell death associated with 
brain ischaemia.
1.11.5 The Role of Kinases in Brain Ischaemia
The role of kinases in ischaemic injury has been studied in several different model 
systems. Their inhibition in vitro and in vivo, has limited neurodegeneration (reviewed 
in Irving and Bamford 2002; Chu et al. 2004) however, their specific pathways are 
still not fully elucidated.
Glycogen synthase kinase 3(3 (GSK3p) has also been implicated in models of neuronal 
cell death (Cross et al. 2001; Facci et al. 2003). Lithium, as well as being an inhibitor 
of inositol monophosphatase (Atack 1996), has been shown to be an effective 
inhibitor o f GSK3a and (3 and protective in models of neurodegeneration as an
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inhibitor of GSK3 (Schafer et al. 2004). Although some studies contest the specificity' 
o f lithium as a GSK3 inhibitor (Pardo et al. 2003), the use o f more specific inhibitors 
of GSK3 have provided further evidence that GSK3 plays a role in neurotoxicity and 
highlights it as a potential therapeutic target (Facci et al. 2003).
The stress associated MAPKs have been shown to be important in ischaemic injury, 
activated by mechanisms such as the formation of ROS (Li et al. 2005). Activation of 
the stress associated MAP kinases JNK and p38 have been shown to be induced in 
different forms o f neuronal apoptosis (Cao et al. 2004), furthermore inhibition of p38 
and JNK have been shown to be neuroprotective in vitro and in vivo (Harper and 
LoGrasso 2001; Hirt et al. 2004; Okuno et al. 2004). Interestingly, recent 
investigations have implicated growth associated MAP kinases with oxidative 
neuronal cell death. In a study o f Alzheimer’s disease brains, the 
hyperphosphorylation within neurones was linked with an activation o f ‘extracellular 
related kinase’ (ERK) (Veeranna et al. 2004). In this model ERK activation was 
downstream of calpain activation suggesting kinase activity was a late event in cell 
death progression. Similarly, in a different model o f oxidative glutamate toxicity, 
ERK activation was not only associated with cell death but furthermore, inhibition o f 
ERIC activation was shown to be neuroprotective (Stanciu et al. 2000). This was later 
shown to be due to the oxidation and inhibition of upstream ERK directed 
phosphatases (Levinthal and Defranco 2004). These recent findings hypothesise a 
possible alternative role for ERIC within neurones following oxidative injury.
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1.12 The Vulnerable Hippocampus
In vivo studies have shown that following global ischemia the hippocampus is one o f 
the major regions affected by ischaemia (Kirino and Sano 1984). It is known that the 
hippocampus is particularly vulnerable to ischemic death, possibly due to the high 
expression o f phospholipase A2 (PLA2) which is involved in the arachadonic acid 
cascade thought to contribute to neurodegeneration by the production o f reactive 
oxygen species (ROS) (Arai et al. 2001; Sun et al. 2004). Indeed, inhibition o f certain 
PLA2S limits ischaemically-induced damage (Yagami et al. 2002). Studies looking at 
multiple brain sections reveal calpain and caspase activation in the hippocampus 
following brain injury (Pike et al. 1998). Features of apoptosis such as caspase-3 
activation and pyknotic nuclei, have been detected in the hippocampus soon after 
ischaemia (Tanaka et al. 2002; Rami 2003; Shin et al. 2004). Further studies using 
global ischemia also show the activation o f specific apoptotic proteins in the 
hippocampus such as Bax and Bad (Krajewski et al. 1995; Abe et al. 2004). These 
studies highlight the hippocampus as a region o f the brain particularly vulnerable to 
ischaemia-induced apoptosis and as a result many studies have concentrated 
specifically on the hippocampus when looking at ischaemic damage (Pulsinelli et al. 
1982; Kirino and Sano 1984; Jin et al. 2001; Niwa et al. 2001; Rami 2003).
1.13 HT22 cell line
The HT22 cell line is a neuronal cell line, derived from the HT4 immortalised murine 
hippocampal cell line and was originally selected for its sensitivity to glutamate 
toxicity (Morimoto and Koshland 1990). The sensitivity to glutamate was discovered 
to be due to a depletion o f glutathione as described above. As such the HT22 cell line 
has been an extremely useful model for the study o f glutamate-induced oxidative
54
stress. Furthermore, HT22 cells contain no flinctional glutamate, oestrogen or 
cannabinoid receptors (Behl et al. 1995; Tan et al. 2001; Marsicano et al. 2002). They 
have yet to be studied for sensitivity to death receptor ligands or antibodies.
1.14 Fluorescence Resonance Energy Transfer (FRET)
For many years researchers have taken advantage o f fluorescence resonance energy 
transfer (FRET) to analyse the interaction of biological molecules. Initial work 
concentrated on the fluorescent labelling o f biological molecules and used FRET as a 
‘spectroscopic ruler’ to observe interactions (Stryer 1978). Since then a number o f 
constructs have evolved to look at the activation o f cellular enzymes (Onuki et al. 
2002; Rehm et al. 2002; Luo et al. 2003). This study has employed the use o f a novel 
FRET construct to study the activation o f caspase-3 in a model o f ischaemic 
apoptosis. This novel FRET construct contains the modified green fluorescence 
protein EYFP (enhanced yellow fluorescence protein) as the donor molecule and 
DsRed (Discoma Red), a fluorescence molecule originally isolated from coral, as the 
acceptor molecule. These molecules are linked by a short peptide linker sequence 
containing the caspase-3 cleavage site DEVD. Upon cleavage o f the peptide sequence 
by caspase-3, FRET is attenuated resulting in a shift from orange to green 
fluorescence (see Figure 1.16).
Despite the presence o f alternative FRET based caspase probes available (Onuki et al. 
2002; Luo et al. 2003; Wu et al. 2005) this novel FRET construct is the only available 
construct to utilise the high wavelength fluorophore DsRed. Previous constructs have 
a design based on GFP derivatives such as CFP combined with YFP (Vanderklish et 
al. 2000; Onuki et al. 2002; Luo et al. 2003; Wu et al. 2005) which require an
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excitation o f ~430nm. Excitation at such a low wavelength often requires lasers that 
are not standard in equipment such as flow cytometers. However the DsRed/EYFP 
construct is able to be analysed at 488nm which gives potential for use in flow 
cytometric analysis, as well as confocal microscopes (Erickson et ak 2003).
56
Active Caspase-3/
Figure 1.16: Structure of the FRET construct used to measure the activation of 
caspase-3.
A, upon activation o f the FRET construct at 488nm the donor fluorophore EYFP is 
excited resulting in the release o f green fluorescence. This fluorescence is partially 
absorbed by the acceptor fluorophore DsRed resulting in the release o f red 
fluorescence. B, in the presence o f active caspasc-3 the linker sequence is cleaved 
resulting in the loss o f absorbance by DsRed and the enhanced fluorescence o f EYFP.
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1.15 Aims of the study
An upregulation of the CD95 receptor and the increased extracellular glutamate as 
observed following an ischaemic insult will be used as a basis for the study of 
ischaemic injury in the HT22 murine hippocampal cell line. The following specific 
aims will be addressed:
1. Cell death induced by CD95.
a. Induce and characterise molecular mechanisms CD95 mediated 
apoptosis and compare with staurosporine-induced apoptosis.
b. Elucidate a possible mitochondrial involvement in CD95-induced 
apoptosis.
2. Oxidative toxicity induced by glutamate.
a. Study the possible apoptotic characteristics o f oxidative neuronal cell 
death.
b. Identify the role o f proteases and kinases in oxidative damage. 
Furthermore this study will characterise the pFRET-Casp3 construct via expression in 
the HT22 cell line and utilise these two models o f cell death to determine its 
effectiveness in detecting DEVDase activity.
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2 MATERIALS AND METHODS
5 9
2.1 Materials
Dulbecco’s Modified Eagle Medium (DMEM) and foetal bovine serum (FBS) were 
purchased from Invitrogen, Paisley UK. L-Glutamine, penicillin/streptomycin, 
cycloheximide (CHX), Trypsin-EDTA, dimethyl sulphoxide (DMSO), glutamate 
(supplied in the form of L-Glutamic acid, sodium salt), saponin, poly-L-lysine, 
Hoechst, LiCl, cyclosporine A, dexamethasone, dithiothreitol, (3-estradiol (E2), 
cyclosporine A, Triton-X-IOO, dithiothreitol (DTT), suramin, propidium iodide (PI), 
RNaseA and kanamycin were all purchased from Sigma-Aldrich, Poole UK. 
Digitonin, CHAPS, Tween-20 and ponceau S were purchased from VWR 
International, Poole UK. Phosphate buffered saline (PBS), tryptone, bacterial agar 
and yeast extract were purchased from Oxoid, Basingstoke UK. Glycerol, NaCI, 
MgCl2(.6 H2 0 ), paraformaldehyde, Tris and methanol were purchased from Fisher 
Scientific, Loughborough UIC. Ethanol was purchased from Hayman Ltd Witham 
UK. The Jo2 monoclonal hamster anti-CD95 antibody, anti-active caspase-3 
detection kit, monoclonal mouse anti cytochrome c antibodies (for western blot and 
immunocytochemistry detection) and rabbit polyclonal anti-fodrin antibodies were 
purchased from BD Pharmingen, Oxford UK. Staurosporine and Suc-Leu-Leu-Val- 
Tyr-AMC (Suc-LLVY-AMC) were purchased from Alexis Biochemicals, Bingham 
UK. LDH cell death detection kits, bovine serum albumin (BSA), TPCK (L-I- 
Chloro-3-[4-tosylamido]-4-phenyl-2-butanone), PEFA block and FuGENE 5 
transfection reagent were purchased from Roche, Lewes UK. Z-Val-Ala-DL-Asp- 
fluoromethylketone (Z-VAD-FMK), Ac-Leu-Glu-His-Asp-aldehyde (Ac-LEHD- 
CHO), Ac-Ile-GIu-Thr-Asp-aldehyde (Ac-IETD-CHO), Ac-Asp-Glu-Val-Asp-CHO 
(Ac-DEVD-CHO) and Ac-Asp-GIu-Val-Asp-AFC (Ac-DEVD-AFC) were purchased 
from Bachem, Bubendorf, Switzerland. The cathepsin B inhibitor (CBI), and the
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caspase inhibitor Qiiinoline-Val-Asp(OMe)-CH2-0 -Ph (Q-VD-OPH) were purchased 
from Enzyme systems, Livermore CA. The MAP kinase inhibitors PD98059, 
SB203580, SP600125 and the SP600125 negative control and the protease inhibitors 
Z-Phe-Ala-CH2F (Z-FA-FMK), [L-3-trans-(Propylcarbamoyl)oxirane-2-carbonyl]-L- 
isoleucyl-L-proline Methyl Ester (CA-074) and N-Acetyl-Leu-Leu-Nle-CHO (ALLN) 
were purchased horn Calbiochem, Nottingham UK. BioRad protein reagent, 
kaleidescope marker, glycine and Bis-/acrylamide were purchased from BioRad, 
Hercules CA. Milk powder was purchased from Marvel, Spalding UK. 
Nitrocellulose membranes were purchased from Amersham, Piscataway, NJ. ECL 
detection kits were purchased from Pierce, Rockford, IL, Mouse monoclonal (B-9) 
and swine polyclonal (N-20) anti-Bax antibodies were purchased fiom Santa Cruz 
Biotechnology, Santa Cruz, CA. All HRP conjugated and FITC conjugated secondary 
antibodies were purchased from DAKO, Ely UK. Vectashield™ was purchased from 
Vectorlabs, Burlingame CA. All cell culture plastic ware was purchased from NUNC 
Roskilde, Denmark.
2.2 Cell Biology
2.2,1 Cell culture of HT-22 cells.
HT-22 cells were a gift from Dr Pamela Maher La Jolla Research Institute, California. 
Cells were grown at 37°C in a 5% CO2 humidified atmosphere in DMEM containing 
10% FBS, 2mM L-glutamine and 50 U/ml penicillin and 50).ig/ml streptomycin. Cells 
were passaged every 3-4 days using trypsin-EDTA dissociation.
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2.2.2 Cytotoxicity
Immediately before treatment 10% FBS/DMEM was aspirated and replaced with 
DMEM containing only 2% FBS. Cells were then treated with 2pg/ml or 200ng/ml 
Jo2 monoclonal hamster anti-CD95 antibody plus Ipg/ml cycloheximide (CHX) in 
dimethyl sulphoxide (DMSO). CHX alone or untreated and incubated for up to 30 
hours. For staurosporine assays, cells were treated with IpM staurosporine in DMSG, 
DMSG alone or untreated. For glutamate toxicity assays cells were treated with 1 -  
lOOmM glutamate in sterile milli Q water and incubated for up to 24 hours.
2.2.3 LDH assay
Cells were seeded at 8  x 10  ^ cells/ml into 24 well plates and incubated overnight at 
37°C, 5% CG] prior to treatment. Following cytotoxicity treatments, llOpI aliquots 
o f medium were removed at 0, 3, 6 , 24 and 48 hours post treatment and assayed for 
LDH activity according to manufacturers instructions. Briefly aliquots were spun at 
IBOOOrpm to remove debris then 100p,l aliquots removed to 96 well plates. Samples 
were incubated with lOOpI o f LDH assay reagent (according to manufacturer’s 
instructions) for <30minutes. Cell death is recorded as a percentage o f total lysis as 
calculated from treatment with 0.1% Triton-X-100 at the end of each experiment. 
Background controls were assayed using 1 lOpl of 2% FBS/DMEM only.
2.2.4 Serum deprivation
Cells were seeded as described above for LDH assay however, following overnight 
incubation 10% FBS/DMEM was removed and replaced with fresh 10%, 2% or 0.5% 
FBS/DMEM. Samples were then incubated for 24 hours at 37°C before finally fresh
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medium was applied (10, 2 or 0.5% as above) prior to glutamate addition. Samples 
were assayed for LDH release as described above.
2.3 Immunology
2.3.1 Caspase-3 detection: Flow cytometry
For active caspase-3 detection; HT-22 cells were seeded at 1.5 x 10  ^ cells/ml into 
25cm^ flasks and treated with CHX only, anti-CD95 antibody + CHX or remained 
untreated as described above. Following incubation with cytotoxic agents, cells were 
removed using ti'ypsin-EDTA dissociation and all medium and cells were collected 
and centrifuged (1,000 rpm for 5 minutes). Medium was then discarded and the cells 
washed twice in cold PBS. Cells were then fixed and stained using a phycoerythrin 
(PE) conjugated monoclonal anti active caspase-3 antibody kit. Cells were analysed 
using a Beckman Coulter Epics XC flow cytometer (Beckman Coulter, Fullerton, 
CA.). A minimum o f 10,000 events were acquired in list mode, while gating the 
forward and side scatters to exclude cell debris, and analyzed in FL-2 for neo-epitope 
appearance.
2.3.2 Cytochrome c/Bax localisation: Flow cytometry
HT-22 cells were seeded at 1.5 x 10  ^ cells per ml into 25cm“ flasks in 10%
FBS/DMEM and incubated at 37°C, 5% CO2 overnight. Following treatment of cells
with cytotoxic agents, medium was collected. Cells were removed from the flasks
using trypsin-EDTA dissociation and added to previously removed medium. Cells
were then centrifuged (2500rpm for 3 minutes). Cells were washed once in PBS and
twice in buffer A (20mM NaCl, lOOmM KCl, 2mM MgCl2(.6 H2 0 ), ImM EGTA,
25mM HEPES, IpM  cyclosporine A, pH 7.1). Following washes cells were
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permeabilised using 700pg/ml digitonin in buffer A for 2 minutes. A minimum o f 
90% permeabilisation was confirmed using trypan blue staining. Following 
permeabilisation, cells were fixed using 1ml o f fixing buffer (4% paraformaldehyde, 
in PBS, pH 7.2) and incubated at 4°C for 20 minutes. Following fixation cells were 
washed three times in blocking buffer (3% BSA and 0.05% Saponin in PBS pH 7.2). 
Samples were incubated at 4°C overnight in primary antibody diluted 1:100 in 
blocking buffer. Cytochrome c detection was performed using a 6H2.B4 monoclonal 
mouse anti-cytochrome c antibody and Bax detection using a B-9 monoclonal mouse 
anti-Bax antibody. Samples were washed 3 times in blocking buffer and incubated in 
FITC conjugated rabbit anti-mouse antibody diluted 1:100 in blocking buffer for 1 
hour at room temperature. Samples were washed 3 times in blocking buffer and 
finally resuspended in 0.5mls PBS. Cells were analysed using a Beckman Coulter 
Epics XC flow cytometer (Beckman Coulter, Fullerton, CA.). A minimum of 10,000 
events were acquired in list mode, while gating the forward and side scatters to 
exclude cell debris, and analyzed in FL-1 for neo-epitope appearance (Bax) or loss 
(cytochrome c).
2.3.3 Activated Bax detection: Flow cytometry
Harvested cells were washed twice in PBS, followed by permeabilisation/fixation and 
resuspension in polyclonal N-20 rabbit anti-Bax antibody (1:100, overnight, 4°C). 
Following washing, samples were exposed to FITC conjugated swine anti rabbit 
secondary antibody (1:100, 1 hour, room temperature). Washed samples were then 
analysed using a Beckman Coulter Epics XC flow cytometer. A minimum of 10,000 
events were acquired in list mode, while gating the forward and side scatters to 
exclude cell debris, and analyzed in FL-1 Bax immunoreactivity. Active Bax was
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identified using the N-terminal specific N-20 antibody (1:100), previously shown to 
be specific to the activated form of Bax (Marani et al. 2002; Korhonen et al. 2003).
2.3.4 Cytochrome c/Bax localisation: Immunocytochemistry
Coverslips (13mm) were sterilised by immersion in 100% ethanol and placed in 24 
well plates. lO^ig/ml o f poly-L-lysine was then applied to each well and incubated at 
37°C for one hour. poly-L-lysine was then removed and wells washed once in 
distilled water. 5.0 x 10  ^ cells/ml (treatment wells) or 1.6 x lO'* cells/ml (control 
wells) of HT-22 cells were seeded in 1ml onto poly-L-lysine treated 13mm coverslips 
in 24 well plates and incubated at 37°C/5% CO2 for 48 hours or until treatment wells 
had reached 80-90% confluence. Following incubation of 24, 27 or 30 hours, cells 
were washed once in PBS and fixed in 4% paraformaldehyde for 30 minutes at 4°C. 
Following fixation cells were washed once in blocking buffer (3% BSA and 0.05% 
Saponin in PBS, pH 7.2) and incubated overnight at 4°C in lOOpl o f 6H2.B4 
monoclonal mouse anti-cytochrome c antibody or B-9 monoclonal mouse anti-Bax 
antibody diluted 1:100 in blocking buffer. Following washes in blocking buffer cells 
were then incubated in lOOpl of 1:100 diluted FITC conjugated anti-mouse antibody 
in blocking buffer for 1 hour at room temperature. Coverslips were washed three 
times in blocking buffer and finally 0.5ml PBS. Coverslips were then removed and 
mounted onto glass slides using 2p.l Vectashield™ mounting medium and sealed with 
nail varnish. Cells were visualised using Zeiss LSM 510 META confocal microscope 
using a 488nni argon laser line, or a Zeiss Axiovert 135 TV epifluorescence 
microscope (Carl Zeiss Ltd. Welwyn Garden City, UK).
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2.3.5 Western blotting
23.5,1 Preparation o f  cell protein
HT-22 cells were seeded at 1.5 x 10  ^ cells/ml into 25cm^ flasks in 10% FBS/DMEM 
and incubated at 3 7° C/5 % CO2 overnight. Following treatment of cells with cytotoxic 
agents, medium was collected. Cells were removed from the flasks using trypsin- 
EDTA dissociation and added to previously removed medium before being 
centrifuged (2500rpm, 3 minutes). For extraction o f cytosolic extracts, cells were 
washed once in PBS and twice in ice cold buffer A (20mM NaCl, lOOmM KCl, 2mM 
MgCl2(.6 H2 0 ), ImM EGTA, 25mM HEPES, IpM cyclosporine A, pH 7.1). 
Following washes, cells were permeabilised using 700j.ig/ml digitonin in buffer A for 
2 minutes. 95% permeabilisation was confirmed using trypan blue staining. Samples 
were spun at 2500rpm for 5 minutes and the supernatant (cytosolic fraction) removed 
and stored at -80°C. The remaining pellet was resuspended in lysis buffer (0.15M 
NaCl, 50mM Tris-HCl (pH7.5), 0.002% SDS, 1% Nonidet P40 (NP40), ImM 
Na3V0 4 , Ipg/ml Leupeptin, Ipg/ml Aprotinin, l|Lig/ml Pepstatin) and centrifuged at 
13,000rpm for 15 minutes at 4°C before being stored at -80°C (mitochondrial 
f  action). For collection o f the whole cell f  action, whole cell pellets were 
resuspended in lysis buffer, centrifuged at 13,000rpm for 15minutes at 4°C and stored 
at -80°C.
Protein concentrations were determined using BioRad protein assay according to 
manufacturers instructions, and read using a Kontron Uvicon spectrophotometer 
(Kontron Instruments, Milton Keynes UK).
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23.5.2 Gel electrophoresis
15% polyacrylamide gels (0.375M Tris-HCl (pH8 .8 ), 15% acryhbis-acrylamide 
(37:1), 0.002% SDS, 0.0015% ammonium persulphate, 0.0003% TEMED) were 
prepared for small protein analysis (cytochrome c, Bax) and 6 % gels (0.375M Tris- 
HCl (pH8 .8 ), 6 % acryhbis-acrylamide (37:1), 0.002% SDS, 0.0015% ammonium 
persulphate, 0.0003% TEMED) were prepared for higher molecular weight proteins 
(Fodrin). Each gel was prepared with a 4% stacker gel (0.125M Tris-HCl (pH6 .8 ), 
4% acryhbis-acryiamide (37:1), 0.002% SDS, 0.001% ammonium persulphate, 
0.003% TEMED). 50jug o f protein was incubated at 95°C for 5 minutes along with an 
equal volume o f loading buffer (0.125M Tris-HCl (pH 6 .8 ), 0.04% SDS, 40% w/v 
glycerol, 0.05% P-mercaptoethanol, 0.0001% Bromopheno! blue). Samples and 
loading buffer were loaded into separate wells in the stacker gel, along with a pre­
stained kaleidescope marker. Gels were run at 120V for 1.5-2 hours at room 
temperature in running buffer (25p,M Tris, 192pM glycine, 0.1% SDS, pH 8.12),
2.3.5.3 Blotting and developing
Following electrophoresis gels were blotted to a Hybond™ nitrocellulose membrane 
in transfer buffer (25|.iM Tris, 192p,M Glycine, 20% Methanol) for 2-18 hours at 4°C. 
Protein transfer was confirmed by staining the membranes in Ponceau buffer (0.2% 
Ponceau S, 3% trichloroacetic acid, and 3% sulfosalicylic acid) for 5 minutes. 
Ponceau was removed by washing the membranes 3 x in water. Membranes were 
incubated in primary antibody diluted as required in milk buffer (5% skimmed milk 
powder in TBST (40mM Tris, 275pM NaCl, 0.2% Tween-20, pH 7.6)) overnight at 
4°C. Membranes were washed 3 x in TBST before being incubated in secondary
antibody diluted 1:1000 in milk buffer for 1 hour at room temperature. Membranes
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were developed using a Pierce ECL detection kit according to manufacturer’s 
instructions.
2.4 Nuclear/DNA staining
2.4.1 Hoechst 33258 staining
HT-22 cells were seeded onto poly-L-lysine treated 13mm coverslips as described 
above. Following treatment with cytotoxic agents, cells were washed once with 1ml 
o f PBS and fixed in 4% formaldehyde (in PBS) for >2 hours at 4°C. Following 
fixation cells were washed once in PBS. 1ml o f PBS was then applied to each well 
and 2|.il o f a Ipg/ml Hoechst stock was applied to each well and incubated for 5 
minutes at room temperature. Finally cells were washed once in PBS before being 
mounted as described above. Cells were visualised on a Zeiss Axiovert 135 TV 
fluorescence microscope (Carl Zeiss Ltd. Welwyn Garden City, UK) using iiv 
excitation and broad field emission.
2.4.2 Draq5 staining
HT-22 cells were seeded onto poly-L-lysine treated 18mm coverslips at 30,000 
cells/ml and incubated overnight. Following treatment with cytotoxic agents (see 
above), cells were washed once with 2mls o f PBS and fixed in 4% formaldehyde (in 
PBS) for >2 hours at 4°C. Following fixation cells were washed once in PBS and 
stained with luM draq5 chromatin dye in PBS for ~2 minutes. Finally coverslips 
were mounted onto glass slides in glycerol/PBS (50:50) mounting solution. Samples 
were viewed with a Zeiss 510 META confocal microscope at an excitation o f 633nm 
and emission field o f 690-7lOnm.
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2.4.3 Propidium Iodide staining for confocal analysis
HT-22 cells were seeded onto poly-L-lysine treated coverslips as described above. 
Following treatment with c)dotoxic agents cells were washed once in PBS before 
being fixed in 4% paraformaldehyde as described above. Following fixation, cells 
were washed once in PBS and following counterstaining (if required), coverslips were 
then mounted onto glass slides using Vectashield™ containing lOpM propidium 
iodide (PI). Coverslips were then sealed using nail varnish. Cells were visualised on 
a Zeiss 510 META confocal microscope. For dial visualisation with FITC, samples 
were excited using 488 and 543nm excitation. The emission channel was split at 
545nm enabling visualisation o f PI (>545nm) and FITC (<545nm).
2.4.4 Cell cycle analysis
HT22 cells were seeded at 2.0 x I O'* cells/ml in 125cnf flasks treated with cytotoxic 
agents as described above. Following treatment cells were harvested via 
trypsinisation retaining all medium. Samples were pelleted at 2000rpm for 5 minutes 
and gradually resuspended drop-wise in fixing buffer (70% ethanol, 30% PBS). 
Following overnight fixation at 4°C overnight samples were washed with ice cold 
PBS and resuspended in PI solution (lOpg/ml PI, Ijig/ml RNaseA in PBS). Samples 
were stained at 37°C for 30minutes and immediately analysed by flow cytometry. A 
minimum of 1 0 ,0 0 0  events were acquired in list mode, while gating the forward and 
side scatters to exclude cell debris and further gating in the auxiliary scatter and FL3 
florescence to remove doublets before finally being analyzed in FL-3 for cell cycle 
distribution.
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2.5 Protease Assays
2.5.1 DEVDase assay
For assessment o f DEVDase activity' cells were seeded at 2 x 10  ^ cells/ml in 125cnf 
flasks and treated with glutamate as described above. Flasks were harvested using 
trypsin/EDTA dissociation and all medium/cells were pelleted by centrifugation at 
1000 X g for 5 minutes and washed once in PBS. Cell pellets were resuspended in an 
equal volume o f ice cold caspase lysis buffer (40mM Sucrose, 50mM NaCl, 5mM 
EGTA, 2mM MgCl2(.6 H2 0 ), lOmM HEPES, pH 7). Pellets were freeze thawed 3 
times to extract protein and the supernatant harvested following centrifugation at 
15,000 X g. 80pg of protein from each sample was assayed for DEVDase activity 
with 40|iM Ac-DEVD-AFC and made up to a final volume o f lOOgl with caspase 
assay buffer (lOOniM Hepes, 10% Sucrose, 0.1% CHAPS, lOmM dithiothreitol, pH 
7.25). Samples were read at an absorbance o f 355nm and emission o f 480nm over a 
period o f 2  hours.
2.5.2 Calpain Activity
For assessment o f calpain activit)', HT22 cells were seeded at 2 x 10  ^ cells/ml in 
125cnf flasks were treated with glutamate as described above. Flasks were harvested 
using trypsin/EDTA dissociation and all medium/cells were pelleted by centrifugation 
at 1000 X g for 5 minutes and washed once in PBS. Cell pellets were resuspended in 
50pl ice cold assay buffer (115mM NaCl, ImM KH2PO4, 5mM KCl, 2mM CaCb, 
1.2mM MgS0 4 , 25mM HEPES, pH 7.4). 25pl o f each sample were placed in 
duplicate wells o f a black 96 well plate. One o f each o f the duplicates were assayed 
with calpain assay substrate (Suc-LLVY-AMC) (60pM) only and the remaining with 
calpain assay substrate + ALLN (50pM). Samples were read at an absorbance of
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355nm and emission o f 460nm over a period o f 2 hours. Results were expressed as 
uninhibited samples minus the inhibited samples (i.e. those treated with ALLN).
2.6 Molecular Biology
2.6.1 Transfection
HT-22 cells were seeded between 1.6 and 7.5 x lO'* cells/ml in 10% FBS/DMEM and 
incubated overnight at 37°C in a 5% CO] atmosphere. The following day 10% 
FBS/DMEM was aspirated and replaced with serum flee DMEM supplemented with 
2mM L-glutamine and 50 U/ml penicillin and 50jLig/ml streptomycin. Each flask was 
transfected with a 3:2 ratio o f FuGENE transfection reagent (6 pl) to pFRET-Casp3 
DNA (4pg), according to manufacturer’s instructions. Flasks were incubated at 37°C 
in a 5% CO? atmosphere for 3 to 8  hours before being supplemented with 10% FBS. 
Confocal images were recorded (Zeiss 510 META) using a 488nm argon laser 
excitation, with the emission channel split at 545nm enabling separation o f EYFP 
(<545nm) and DsRed (>545nm).
2.6.2 Plasmid growth and harvest (mini preps).
Competent E. Coii (DH5a) were incubated on ice for 30 minutes with ~4pg of 
plasmid before being exposed to 42°C for 45 seconds. The bacterial/plasmid were 
then incubated in 200pl o f Lurici-Bertani (LB) broth (1% w/v tryptone, 0.5% yeast 
extract and 1% w/v NaCl) at 37°C for 30 minutes and plated onto nutrient agar (LB 
Broth + 1.5% agar) containing 50p.g/ml kanamycin at 37°C overnight. Following 
incubation individual colonies were picked and grown in 5mls LB broth + 50p,g/ml 
kanamycin with shaking overnight.
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Transformed bacteria were then centrifuged (SOOOrpm, 1 minute) before being 
resuspended in lOOp.1 o f resuspension buffer (50mM Glucose, 25mm Tris pH8 , lOmM 
EDTA) and mixed thoroughly. Cells were lysed by the addition o f 200 j l i1 lysis buffer 
(1% SDS, 0.2M NaOH) and gentle mixing before being neutralised with 150pl 
neutralisation buffer (3M potassium acetate, 11.5% glacial acetic acid). Bacterial 
genomic DNA was precipitated on ice for 5 minutes and pelleted by centrifugation at 
14,000rpm for 5 minutes. 400^il o f 5:1 phenol/chloroform was added to the 
supernatant and the top phase transferred to a fresh tube. Plasmid DNA was 
precipitated by the addition o f 1ml 1 0 0 % ethanol, incubation at room temperature for 
10 minutes and centrifugation at 14,000rpm for 15 minutes. The pellet was washed in 
70% ethanol before being centrifuged and incubated at 37°C in RNAse/TE buffer 
(1 mg/ml RNAse, lOmM Tris, ImM EDTA, pH 8 ).
2.7 FRET construct analysis
2.7.1 Plasmid construction
Meinander, A., Mikhailov, A. and Eriksson, J. E. (see Elphick et al. 2005)
A 19 amino acid peptide chain encoding the caspase-3 cleavage site, 
GS(BspEI)GGSGSGDEVDNGSGSGS(BamHI), was added in front o f the start codon 
of pDsRed2-Nl (Clontech, CA, USA) by PCR cloning. The cDNA for the peptide 
sequence along with that o f pDsRed2-N 1 was then digested with BspEI and EcoRl 
and subcloned into the multiple cloning site of pEYFP-Cl (Clontech, CA, USA) to 
generate pFRET-casp3.
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2.7.2 Fluorimetric analysis
HT-22 cells transfected in 125cm^ cell culture flasks were harvested by trypsin-EDTA 
dissociation and washed once in PBS. Pelleted cells were then resuspended in an 
equal volume o f cell lysis buffer (40mM sucrose, 50mM NaCl, 2mM MgCl2(.6H20), 
5mM EGTA and lOmM HEPES, pH7.0) and freeze-thawed 3 times. Cell debris was 
removed by centrifugation at 2,500rpm for 5 minutes, supernatants aliquoted and 
stored at -80°C until required. For spectrum analysis, ISpl samples were transferred 
to black 96 well plates with 50p,l caspase assay buffer (50mM HEPES, 50mM NaCl, 
0.1%w/v CHAPS, lOmM EDTA, 5% w/v glycerol and lOmM dithiothreitol (DTT), 
pH 7.2). Spectra were read in a SpectraMAX Gemini XS fluorescence plate reader 
(Molecular devices, Wokingham UK) at an excitation o f 490nm and emission at 
530nm for EYFP and 595 for DsRed (unless otherwise stated) with intervals o f lOnm. 
Endpoint readings were taken using 490nm excitation and emission readings at 
530nm (EYFP) and 585nm (DsRed). Ratios were calculated by dividing the emission 
at 585nm by emission at 530nm,
2.7.3 Differential counting (live cell analysis)
Flasks (25cm^) of transfected HT-22 cells (see above) were viewed using 
epifluorescence microscopy (488nm excitation, broad emission filter). Caspase-3 
activity was quantified by counting >100 fluorescent cells in random fields o f view 
and recording the number o f orange and green fluorescent cells within that population.
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3 CD95 INDUCED APOPTOSIS & FRET
CONSTRUCT DEVELOPMENT
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Introduction: Chapter 3
The overall aim of this study is to further understand the molecular pathways 
associated with neuronal cell death. This first chapter aims to characterise the 
apoptotic pathway induced by activation o f the CD95 death receptor in neuronally 
derived HT22 cell line. This model will also be used to develop, validate and test the 
efficiency o f a caspase-3 DsRed/EYFP FRET construct both in vitro and within living 
cells.
As no previous work has demonstrated the apoptotic ability of the CD95 death 
receptor in HT22 cells this chapter will use the apoptotic inducer staurosporine, 
known to induce apoptosis in a wide range o f cell lines, to compare apoptotic features 
as well as caspase-3 activation and FRET construct cleavage.
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3.1 Anti-CD95 antibody and Staurosporine cell death in 
HT-22 cells
To verify whether HT-22 cells are susceptible to staurosporine and CD95 induced cell 
death, cells were incubated for 48 hours with 200ng/inl anti-CD95 only, 200ng/ml 
anti-CD95 + Ipg/m l CHX or IpM  staurosporine. Figure 3.1 illustrates that IpM  
staurosporine induces significant cell death; however, HT-22 cells require the addition 
o f CHX in order to be susceptible to CD95 induced apoptosis. CHX alone induced a 
small but significant level o f cell death at 48 hours only. No significant increases in 
cell death were obseived fiom 0.1% DMSO controls.
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Figure 3.1: Staurosporine and anti-CD95 antibody, in combination with 
cycloheximide, induces significant levels of cell death in HT-22 cells.
HT-22 cells were exposed to 200ng/ml anti-CD95 antibody, 200ng/ml anti-CD95 
antibody + Ipg/ml cycloheximide (CHX), CHX alone or 0.1% v/v DMSO (A) or 
IpM  staurosporine and 0.1% v/v DMSO (B). The percentage o f cell death was 
observed over 48 hours using LDH cytotoxicity assay as described in Materials and 
Methods. Comparison o f means were made using a one way ANOVA followed by a 
Tukey-Kramer post hoc, *** = p<0.001 versus CHX control (A), or DMSO control 
(B). ### = p<0.001 versus DMSO control, n > 3.
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3.2 Characterisation of anti-CD95 induced cell death.
In order to determine whether anti-CD95 antibody + CHX induced apoptotic or 
necrotic cell death, HT-22 cells exposed to anti-CD95 antibody and staurosporine 
were stained with the nuclear chromatin dye Hoechst. Figure 3.2 shows diffuse 
nuclear staining was observed in all control samples (A, B & D). Those treated with a 
combination o f anti-CD95 antibody + CHX (C) or IpM  staurosporine (E) show 
chromatin condensation (as indicated by arrows) indicative o f apoptotic cell death.
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yFigure 3.2: Anti-CD95 antibody + CHX and staurosporine induce chromatin 
condensation in HT-22 cells.
Fixed cells (4% formaldehyde) previously untreated (A) or treated with IpM  CHX 
only (30 hours) (B), 200ng/ml anti-CD95 + Ipg/ml CHX (3 hours) (C), 0.1% DMSO 
only (24 hours) (D) or IpM staurosporine (24 hours) (E) were stained with 2pg/ml of 
the nuclear dye Hoechst 33258 and viewed under uv optics using epifluorescence 
microscopy. Figure shows representative results o f >3 experiments.
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3.3 Caspase inhibition o f apoptosis
In order to determine whether anti-CD95 antibody induced cell death was dependent 
on caspase activity, HT-22 cells were pre-incubated with the broad spectrum caspase 
inhibitors z-VAD-FMK and Q-VD-OPh and the caspase-3 like inliibitor Ac-DEVD- 
CHO before exposure to cytotoxic agents. As shown in Figure 3.3, caspase inhibitors 
significantly reduced both staurosporine and anti-CD95 induced cell death.
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Figure 3.3: The effect of caspase inhibitors on staurosporine and anti-CD95 
induced cell death.
HT-22 cells were pre-treated with z-VAD-FMK (lOOpM), or Q-VD-OPh (50pM) 
(anti-CD95 -f CHX only) or Ac-DEVD-CHO (50pM), for 30 minutes prior to 
exposure to 1 pM staurosporine for 24 hours (A) or 200ng/ml anti-CD95 antibody + 
Ipg/ml CHX for 48 hours (B). Cell viability was assessed using the LDH assay as 
described in Materials and Methods. Comparison o f means were made using a one 
way ANOVA followed by a Tukey-Kramer post hoc, *** = p<0.001, ** = p<0.01 
versus staurosporine (A) or anti-CD95 antibody + CHX (B), n > 3.
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3.4 Calpain and cathepsin involvement in CD95 induced cell 
death
Caspase inhibitors have previously been shown to inhibit cathepsins (Schotte et al. 
1998) In order to detennine the contribution o f calpains and cathepsins to anti-CD95 
induced cell death HT-22 cells were pre-incubated with the inhibitor z-FA for 30 
minutes prior to exposure to anti-CD95 antibody + CHX. Figure 3.4 shows pre- 
treatment with z-FA resulted in significant inhibition of anti-CD95 antibody + CHX 
induced cell death.
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Figure 3.4: Calpain and cathepsin inhibition attenuates anti-CD95 antibody cell 
death.
Cells were pre-treated with 50pM z-FA-FMK for 30 minutes prior to treatment with 
200ng/ml anti-CD95 antibody and/or Ipg/ml CHX for 24 hours. Cell death was 
assayed via LDH release as described in Materials and Methods. Comparison of 
means were made using a one way ANOVA followed by a Tukey-Kramer post hoc, 
*** = p<0.001 versus anti-CD95 antibody + CHX, ns = not significant versus 
untreated, ns = not significant versus CHX only, n > 3.
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3.5 GSK involvement anti-CD95 antibody induced cell 
death
It has previously been noted that MAP kinases play a role in CD95 mediated cell 
death (Hou et al. 2002). By treating the cells with an inhibitor o f p38 (SB203580) it 
was determined whether inhibition o f MAP kinases limited CD95 mediated HT-22 
cell death. Figure 3.5 shows that SB203580 did not significantly alter anti-CD95 
induced cell death.
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Figure 3.5: Inhibition of MAP kinase p38 fails to inhibit anti-CD95 antibody cell 
death.
Cells were pre-incubated with the specific p38 kinase inhibitor SB203580 (lOpM) for 
30 minutes prior to treatment with 200ng/ml anti-CD95 antibody + Ipg/ml CHX. 
Cell death was assayed via LDH release as described in Materials and Methods. 
Comparison o f means were made using a one way ANOVA followed by a Tukey- 
Kramer post hoc, ns = not significant versus anti-CD95 antibody + CHX, n > 3.
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3.6 Serine protease inhibition of anti-CD95 induced  
apoptosis
The involvement o f serine proteases in CD95 mediated apoptosis has previously been 
demonstrated (Jones et al. 1998). By pre-treating HT-22 cells with the serine protease 
inhibitors PEFA bloc and TPCK the involvement o f these proteases could be 
detemiined in HT-22 cells. As shown in Figure 3.6, neither serine protease inhibitor 
altered CD95 induced cell death. However, TPCK did inhibit staurosporine induced 
cell death. The addition o f PEFA block appeared to affect the assay by reducing the 
absorption at 495nm therefore resulting in a false inhibition o f cell death. No 
differences were obseiwed in CHX treatments or with serine protease inliibitors alone.
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Figure 3.6: The serine proteases TPCK and PEFA fail to inhibit anti-CD95 
antibody induced apoptosis.
HT-22 cells were pre-treated with 300pM PEFA block (A) or lOpM TPCK before 
exposure to 200ng/ml anti-CD95 antibody + Ipg/ml CHX, Ipg/ml CHX alone, IpM 
staurosporine or no further treatment. Cell death was assayed using LDH assay as 
deseribed in Materials and Methods. Comparison o f means o f TPCK treated data at 
48 hours was made using a one way ANOVA followed by a Tukey-Kramer post hoc, 
*** = p<0.001 versus staurosporine, ns = not significant versus anti-CD95 antibody + 
CHX, n > 3.
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3.7 M olecular inhibitors of anti-CD95 antibody induced 
apoptosis
Previous characterisation o f CD95 induced cell death in other cell lines showed that 
different agents may be used to identify the type o f CD95 induced cell death or further 
characterise the molecular mechanisms involved. These included lithium, previously 
shown to enhance CD95 mediated apoptosis (Song et al. 2004), the mitochondrial 
membrane channel blocker cyclosporine A (Tafani et al. 2002), the cell type specific 
anti-apoptotic agent Suramin (Eiclihorst et al. 2004) and the broad range inhibitor 
dexametliasone via phospholipase A2 (PLA2) inhibition (Jaattela et al. 1995). The 
involvement o f these proteins in the HT-22/CD95 system was then studied via 
inhibition assays. As shown in Figure 3.7, neither lithium, cyclosporine A or 
dexamethasone affected cell death as induced from anti-CD95 antibody + CHX. 
Suramin proved to be toxic to HT-22 cells alone and had no effect with anti-CD95 
antibody + CHX.
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Figure 3.7: Resistance of anti-CD95 antibody induced apoptosis in HT-22 cells.
HT-22 cells were pre-treated with 20mM LiCl (A), lOpM cyclosporine A (eyA) (B), 
250pM Suramin (C) or 5pM dexamethasone (D) before exposure to 200ng/ml anti- 
CD95 antibody + Ipg/ml CHX, Ipg/ml CHX alone for 48 hours apart from Suramin 
which was incubated for 30 hours. Cell death was assayed using LDH assay as 
described in Materials and Methods. Comparison o f means were made using a one 
way ANOVA followed by a Tukey-Kramer post hoe, *** = p<0.001 versus control, 
ns = not significant versus anti-CD95 antibody + CHX, n > 3.
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3.8 p-estradiol inhibition of anti-CD95 induced apoptosis
Oestrogen and its related compounds have previously been shown to be 
neuroprotective tlnough receptor mediated and independent mechanisms (Behl et al. 
1995; Green et al. 1998; Garcia-Segura et al. 2001; Jover et al. 2002; Teepker et al. 
2003). To test whether oestrogenic compounds are able to protect HT-22 cells from 
CD95 mediated cell death, HT-22 cells were pre-treated with two concentrations o f (3- 
estradiol, a concentration low enough to induce oestrogen receptors however, low 
enough not to exert antioxidant properties (20nM), and an antioxidant concentration 
(lOpM). As shown in Figure 3.8, neither concentration affected anti-CD95 + CHX 
induced cell death. No significant differences were observed between controls and 
untreated nor between CHX and CHX + (3-estradiol.
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Figure 3.8: P-estradiol failed to inhibit anti-CD95 induced cell death.
HT-22 cells were pre-treated with 20nM (A) or lOpM (B) o f P-estradiol for 30 
minutes before being exposed to 200ng/ml anti-CD95 antibody + Ipg/ml CHX or 
1 fig/ml CHX only. Controls were P-estradiol only or the vector control 0.1% v/v 
ethanol. Cell death was assayed using LDH assay as described in Materials and 
Methods, n > 3.
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3.9 Cytochrome c Release
Cytoclu'ome c is laiown to be involved in the mitochondrial pathway o f apoptosis 
where it is released from the mitochondria to the cytosol (Goldstein et al. 2000). In 
order to characterise whether the mitochondrial pathway is involved in CD95 
mediated HT-22 cell death several methods were employed to study cytochrome c 
localisation in both healthy and CD95 stimulated cells.
Figure 3.9 illustrates control cells (A-F) with a punctuate staining indicative o f 
cytochrome c mitochondrial localisation. Those counterstained with PI show the 
mitochondrial staining to be independent of the nucleus (C & F). Those cells treated 
with apoptotic stimuli show a much more diffuse staining (G-I), typical o f a cytosolic 
localisation. PI staining reveals nuclei with total cytochrome c release following 
exposure to anti-CD95 + CHX (I, as indicated by an ows).
Localisation studies were confirmed using Western blotting techniques. Figure 3.10 
shows that in untreated and CHX treated cell fractions, cytochrome c is predominantly 
localised to the mitochondria. However, following exposure to anti-CD95 + CHX 
cytochrome c translocates to the cytosol. Staining for the mitochondrial cytochrome 
oxidase subunit IV (COX) indicates that the cytosolic fractions were free from 
mitochondrial contamination.
To further confirm cytoclirome c translocation following CD95 stimulation, 
permeabilised HT-22 cells were washed to remove cytosolic cytochrome c before 
being fixed and stained for membrane associated cytoclnome c. Figure 3.11 shows 
flow cytometric analysis o f permeabilised HT-22 cells. A high percentage o f M2
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staining in untreated and CHX samples indicates a predominance o f membrane 
associated cytochrome c. Following exposure to anti-CD95 + CHX the percentage of 
M2 stained cells is significantly reduced suggesting a release of membrane associated 
cytoclnome c. Secondaiy antibody only resulted in no significant staining as 
compared to unstained samples (data not shown).
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Figure 3.9: Anti-CD95 antibody + CHX and staurosporine induce cytochrome c 
release.
Cells were fixed (4% paraformaldehyde) following no treatment (A-B), or treatment 
with DMSO (C), CHX (D-E), staurosporine (F) or anti-CD95 antibody + CHX (G & 
H) for 24 hours. Cytochrome c was localised using an antibody to cytochrome c 
followed by a secondary FITC conjugated antibody. PI was used as a nuclear dye. 
Scale bars represent 20pM. Arrows represent PI stained nuclei with no associated 
cytochrome c staining indicating total loss of cytochrome c. Figure shows 
representative results of >3 experiments.
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Figure 3.10: Cytochrome c translocates from the mitochondrial to the cytosol 
following anti-CD95 + CHX exposure.
50)ig o f mitochondrial or cytosolic cell fractions taken following 24 or 30 hours 
exposure to anti-CD95 antibody and/or CHX or fractions that remained untreated 
were subjected to 15% SDS PAGE followed by ECL detection as described in 
Materials and Methods. Figure shows representative results of >3 experiments.
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Figure 3.11: Flow cytometry analysis of permeabilised cells shows significant 
cytochrome c loss following anti-CD95 antibody + CHX treatment.
HT-22 cells treated as described above were permeabilised with TOOpg/ml digitonin 
before being fixed and stained with monoclonal mouse anti-cytochrome c followed by 
FITC conjugated anti mouse antibody and analysed by flow cytometry. Comparison 
of means were made using a one way ANOVA followed by a Tukey-Kramer post hoc, 
*** = p<0.001, ** = p<0.01, n > 3. M2 represents the proportion o f cells with 
membrane associated eytochome c as compared to untreated controls.
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3.10 Involvement of Bax in anti-CD95 antibody induced cell 
death
A possible upstream initiator o f cytoclnome c release is the pro-apoptotic Bcl-2 
protein Bax (Jurgensmeier et al. 1998). Following confirmation o f cytochrome c 
release following CD95 receptor stimulation in HT-22 cells, Bax localisation was also 
analysed using similar techniques. Figure 3.12 shows Bax staining in HT-22 cells. 
There appeared to be no observable difference in Bax localisation between untreated, 
CHX and anti-CD95 antibody + CHX treated cells using imunocytocliemistry 
tecliniques.
Bax localisation was also analysed by western blotting techniques. In Figure 3.13, 
monoclonal Bax B-9 antibody reveals an increased detection o f Bax within 
mitochondrial fractions, with little to no staining in CHX and untreated mitochondrial 
fractions. Staining for the mitochondrial cytochrome oxidase subimit IV (COX) 
shows a lack o f contamination in cytosolic fractions.
Following confirmation of Bax translocation the activation o f Bax was analysed using 
an antibody to the N terminal epitope o f Bax (N-20). Figure 3.14 shows, via flow 
cytometric analysis, there is a significant increase in Bax staining following exposure 
to anti-CD95 + CHX as compared to CHX only or untreated samples.
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Figure 3.12: Immunocytochemistry of Bax localisation does not show significant 
differences in localisation between untreated and anti-CD95 antibody + CHX 
treated cells.
Fixed cells (4% paraformaldehyde) were stained with monoclonal B-9 anti-Bax 
antibody followed by FITC conjugated anti mouse antibody and viewed using 
confocal microscopy. Scale bars represent 20pm.
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Figure 3.13: Bax translocates from the cytosol to the mitochondria following 
anti-CD95 + CHX exposure.
50pg of mitochondrial or cytosolic cell fractions taken following 24 or 30 hours 
exposure to anti-CD95 antibody and/or CHX or fractions that remained untreated 
were subjected to 15% SDS PAGE followed by ECL detection. Figure shows 
representative results o f >3 experiments.
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Figure 3.14: Flow cytometry analysis of Bax stained ceils reveals increased Bax 
activation.
Following treatments cells were fixed (4% paraformaldehyde) before being stained 
with N-20 anti-Bax antibody and FITC anti rabbit antibody and analysed by flow 
cytometry. Comparison o f means were made using a one way ANOVA followed by a 
Tukey-Kramer post hoc, *** = p<0.001 versus CHX. N = 4. M2 gated represents the 
percentage increase in N-20 (active Bax antibody) staining.
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3.11 Flow cytometric detection of cleaved caspase-3
Caspase-3 is a major effector caspase involved in both CD95 and staurosporine 
induced apoptosis (Zheng et al. 1998; Rehm et al. 2002). Cleavage o f pro-caspase-3 
to the active form of caspase-3 in staurosporine and anti-CD95 + CHX treated cells, 
was detected using flow cytometiy. Active caspase-3 fragments were detected 
following exposure to staurosporine and anti-CD95 + CHX at 24 hours post infection 
as shown in Figure 3.15.
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Figure 3.15: Flow cytometric detection of pro-caspase-3 cleavage in CD95 
stimulated HT-22 cells.
A, sample histograms of CHX (i) and anti-CD95 antibody -t- CHX (ii) treated HT-22 
cells stained with PE conjugated anti-active caspase-3 showing low (b) and high (c) 
fluorescence regions. Figure shows representative results o f >3 experiments. B, 
Timecourse o f increased fluorescence (as gated in region ‘C’). Comparison of means 
at separate timepoints were made using a one way ANOVA followed by Tukey- 
Kramer post hoc, *** = p<0.001, * = p<0.05 versus CHX, n > 3.
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3.12 Expression of pFRET-casp-3 tandem construct in HT- 
22 cells
Following confirmation o f pro-caspase-3 cleavage the activity o f caspase-3 was 
confiimed using FRET-Casp-3. Figure 3.16 shows an orange fluorescence in 
untreated and CHX treated cells, with profiles o f each cell showing a slight increased 
red fluorescence relative to green. Following exposuie to anti-CD95 + CHX cells 
possess a green fluorescence. This is confirmed fiom the profile where cells now 
show a predominance o f green fluorescence with little or no red fluorescence.
103
h  A
Figure 3.16: Expression of pFRET-casp-3 construct in HT-22 cells.
HT-22 cells transfected with pFRET-casp-3 were incubated for 72 hours allowing for 
complete processing o f DsRed and viewed using confocal microscopy (Ex. 488nm). 
Transfected cells remained untreated (A) or incubated with CHX (B) or anti-CD95 
antibody + CHX (C). Profiles represent relative fluorescence o f green (<545nm) and 
red (>545nm) as shown by arrows in image. Scale bars represent 50pM. Figure 
shows representative results o f >3 experiments.
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3.13 Differential counting of pFRET-Casp-3 transfected cells
A timecourse o f transfected cells was obtained showing the increase in green 
fluorescent cells over time. Figure 3.17A shows a significant increase in the 
percentage o f green cells following treatment with anti-CD95 + CHX. Untreated and 
CHX treated cells showed no significant changes over time. Furthermore the increase 
in caspase-3 activity conelates with pro-caspase-3 cleavage following exposure to 
anti-CD95 + CHX as shown in Figure 3.17B.
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Figure 3.17: Differential counting of transfected HT-22 cells reveals caspase-3 
activity at 24 hours post CD95 stimulation.
A, transfected cells incubated for 72 hours were exposed to Ipg/ml CHX, 200ng/ml 
anti-CD95 antibody + Ipg/ml CHX or untreated were incubated and the percentage 
green fluorescent cells counted over 48 hours from separate populations o f <100 
fluorescent cells. B, A comparison o f caspase-3 activation as determined from flow 
cytometry and activity as determined from fluorescent counting. Comparison of 
means at separate timepoints were made using a one way ANOVAs followed by a 
Tukey-Kramer post hoc, *** = p<0.001, * = p<0.05 versus CHX, n > 3.
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3,14 Optimisation of fluorescence plate reader
In order to develop high tlu'oughput methods for the study of FRET-Casp-3, a more 
detailed characterisation would be required. In vitro characterisation of FRET-Casp-3 
was obtained using a fluorescence plate reader. Figure 3.18 shows the optimisation o f 
the excitation wavelength required for fluorescence detection. Maximal emission 
with lowest background was observed using a 490mn excitation.
Figure 3.19 shows the emission spectrum from FRET-Casp-3 using an excitation of 
490nm. FRET-Casp-3 shows a large peak at 530nm from EYFP and a smaller peak at 
585nm from DsRed.
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Figure 3.18: Optimisation of Fluorescence plate detection of EYFP emission.
HT-22 cells transfected with pFRET-Casp-3 were lysed and read in black 96 well 
plates. Excitation was optimised with a fixed emission of 530nm over an excitatory 
range between 350 and 500nm. A =  pFRET-Casp-3 transfected cells, O = 
untransfected cells, □  = buffer only.
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Figure 3.19: Fluorescence plate reader detection of DsRed and EYFP.
Using optimised excitation (490nm) wavelength the spectrum o f FRET-Casp-3 
construct emission was observed in lysed cells. □  = pFRET-Casp-3 transfected cells, 
O  = untransfected cells.
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3.15 Loss of FRET detection
Lysates o f cells treated with staurosporine (i.e. lysates containing active caspases) 
were applied to the FRET construct extract shown in Figure 3.19 and incubated at 4°C 
overnight. Figure 3.20 shows the spectrum of the cell lysate and FRET construct 
where there is a loss o f both EYFP and DsRed, however the loss o f DsRed is greater 
than that o f EYFP.
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Figure 3.20: Loss of EYFP and DsRed fluorescence following incubation with 
caspase extract.
Using the optimised excitation (490nm) wavelength the spectrum o f FRET-Casp-3 
construct following incubation with staurosporine treated cell extract ( IpM for 24 
hours) was observed in lysed cells. □  = pFRET-Casp-3 transfected cells, O  = 
untransfected cells.
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3.16 Detection of DsRed fluorescence
If the relative loss o f DsRed fluorescence was indeed due to the cleavage o f the FRET 
construct, recovery o f red fluorescence should be possible. Figure 3.21 shows the 
recovery o f red fluorescence in lysates from Figure 3.20. The loss o f DsRed 
fluorescence from ~ 50rfu to ~30rfu was recovered to ~40rfu using an excitation 
wavelength o f 525nm.
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Figure 3.21: Detection of DsRed fluorescence.
Using an increased excitation wavelength o f 525nm the spectrum o f DsRed from 
FRET constructs incubated with staurosporine treated cell extract ( IpM for 24 hours) 
was observed in lysed cells. A  = pFRET-Casp-3 transfected cells, □  = untransfected 
cells, O = Buffer only.
I l l
3.17 Ratio calculations in transfected cells
Following spectrum analysis o f FRET-Casp-3 the ratio o f the emissions at 585nm and 
530nm were obtained. Figure 3.22 shows that there is a significant reduction in 
585nm:530nm ratio following exposure to apoptotic stimuli compared to controls.
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Figure 3.22: FRET ratio calculations in transfected HT-22 cells.
Cells untreated or treated with 0.1% DMSO or IpM  staurosporine for 18 hours were 
lysed and read at 490nm and the DsRediEYFP ratios calculated at 585:530nm. 
Comparison of means were made using a one way ANOVA followed by a Tukey- 
Kramer post hoc, ** = p<0.01 versus DMSO. N = 4.
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Summary: Chapter 3
This chapter aimed to characterise CD95 induced apoptosis in the HT22 neuronal cell 
line. This investigation revealed that activation o f CD95 via anti-CD95 antibody and 
CHX sensitisation induces a caspase dependent apoptosis. Furthermore this apoptotic 
phenotype involves chromatin condensation, cytochrome c release, Bax translocation 
and Bax conformational change.
Using this caspase dependent model o f cell death we were also able to show that the 
DsRed/EYFP FRET constmct is able to efficiently detect DEVDase activity in living 
cells. EYFP and DsRed fluorescence was also detected in vitro. Application o f 
caspase active cell extracts (from staurosporine treated cells) resulted in a reduced 
DsRed fluorescence. DsRed fluorescence was maintained and could be detected by 
excitation at 525nm implying that the loss o f DsRed fluorescence was due to cleavage 
o f the FRET constmct rather than loss o f the DsRed fluorophore.
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4 PROTEASE INVOLVEMENT IN OXIDATIVE 
GLUTAMATE TOXICITY
114
Introduction: Chapter 4
This chapter moves away from the apoptotic model o f CD95 induced cell death and 
starts to investigate the molecular mechanisms of oxidative toxicity associated with 
excess glutamate in this cell line. Previous research has failed to conclusively identify 
the major contributing death associated protease related to this model o f oxidative 
glutamate toxicity. Therefore this chapter aims to identify the roles (if any) of 
caspases, calpains and cathepsins following glutamate toxicity in HT22 cells.
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4.1 Glutamate induces dose dependent cell death in HT-22 
cells
As previously reported, Figure 4.1 shows that glutamate induces a dose dependent cell 
death in HT-22 cells. This cell death is thought to be due to a depletion of 
intracellular glutathione levels and can be rescued by anti-oxidants including P- 
estradiol (Figure 4.2).
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Figure 4.1 Glutamate induces dose dependent cell death in HT-22 cells.
HT-22 cells were exposed to concentrations o f glutamate from 0.1 to lOOmM. The 
percentage of cell death was observed following 24 hours treatment with glutamate 
using LDH cytotoxicity assay as described in Materials and Methods. Results were 
analysed using non-linear regression software in GraphPad Prizm, n = 3.
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Figure 4.2 Anti-oxidant levels of P-estradiol rescue HT-22 cells from glutamate 
induced cell death.
HT-22 cells were untreated or exposed to 0.1% milli Q water, 0.1% ethanol lOpM p- 
estradiol only and 1.5 or 3mM glutamate in the presence and absence o f 0.1% ethanol 
only or lOpM p-estradiol dissolved in ethanol. The percentage o f cell death was 
observed following 24 hours treatment with glutamate using LDH cytotoxicity assay 
as described in Materials and Methods. Comparison of means were made using a one 
way ANOVA followed by a Bonferroni's Multiple Comparison post hoc, *** = 
p<0.001 versus ethanol and glutamate, n = 4.
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4.2 The morphology of oxidative glutamate toxicity
To characterise further the morphological features o f oxidative glutamate toxicity in 
HT-22 cells, Hoechst staining was employed to study the changes in the nuclei, flow 
cytometiy was used to look at phosphatidyl serine translocation and 
immunocytochemistry was used to look at the distribution of cytochrome c following 
glutamate stimulation. Figure 4.3 shows that glutamate induces chromatin
condensation in HT-22 cells indicative o f an active form of cell death. Figure 4.4 
shows no translocation o f cytochrome c, as indicated by the presence o f punctuate 
staining. Figure 4.5 indicates no early translocation of phosphatidyl serine as 
indicated by no increase in the number o f cells in the region labelled ‘B4’ as 
compared to controls. The B4 region represents cells which maintain membrane 
integrity but also actively induce phosphatidyl serine tiansfer to the outer surface of 
the cell.
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Figure 4.3 Glutamate induces chromatin condensation in HT-22 cells
Fixed cells (4% formaldehyde) previously untreated (A & D), treated for 18 hours 
with 0.3% milHQ water (B & E) or lOmM glutamate (C & F) were stained with 
2|ig/ml o f the nuclear dye Hoechst 33258 and viewed using fluorescence microscopy 
(A-C), or stained with Ipg/ml o f the nuclear dye draq5 (D-F) and viewed under 
confocal microscopy. Scale bars represent 20pM, available on confocal images only. 
Figure shows representative results o f >3 experiments.
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Figure 4.4 Glutamate induced cell death in HT-22 cells does not involve 
cytochrome c release.
HT-22 cells were either untreated (A) or exposed to 0.3% milHQ water (B) or 3mM 
glutamate (C and D) for 18 hours before being fixed (4% paraformaldehyde) and 
stained with anti-cytochrome c antibody and FITC conjugated secondary antibody. 
Scale bars represent 20pm. Figure shows representative results o f >3 experiments.
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4.3 Broad spectrum protease inhibition
One of the most common group of proteases involved in many types o f cell death are 
the caspases. Assessing their involvement in cell death often initially involves the use 
of a pan caspase inhibitor such as z-VAD-fmk. Figure 4.6 shows z-VAD enhances 
glutamate induced cell death. Furthermore, this increase in glutamate induced cell 
death did not appear to change the nuclear morphology as shown in Figure 4.7 with 
draq5 staining.
100
—  75 
%
30) 50
Figure 4.6 Z-VAD enhances glutamate induced toxicity in HT-22 cells.
HT-22 cells were untreated or exposed to 0.1% milli Q water, 0.1% DMSO, 50pM z- 
VAD only and 3 or lOmM glutamate in the presence and absence of 50pM z-VAD. 
The percentage o f cell death was observed following 18 hours treatment with 
glutamate using LDH cytotoxicity assay as described in Materials and Methods. 
Comparison o f means were made using a one way ANOVA followed by a 
Bonferroni's Multiple Comparison post hoc, *** = p<0.001 and ** = p<0.01 versus 
glutamate only, ns = not significant versus DMSO control, n= 4.
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Figure 4.7 Z-VAD does not alter nuclear morphology.
Fixed ceils (4% formaldehyde) previously treated for 18 hours with 0.3% milliQ 
water (A), 3mM glutamate (18 hours) (B), 50pM z-VAD (C) or 50pM z-VAD + 
3mM glutamate (D) were stained with Ipg/ml draq5 and viewed using confocal 
microscopy. Scale bars represent 20pM. Figure shows representative results o f >3 
experiments.
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4.4 Inhibition of isolated caspases during oxidative 
glutamate cell death
Following the enhancement o f glutamate induced cell death with z-VAD-fmk, the role 
of individual caspases was then investigated by using more specific caspase 
inhibitors. As shown in Figure 4.8 and Figure 4.9, no significant alterations were 
observed from inhibition of caspase-3, caspase-8 or caspase-9 like caspases.
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Figure 4.8 Inhibition of effector caspases has no effect on glutamate induced cell 
death.
HT-22 cells were untreated, exposed to 0.1% milli Q water, 0.1% DMSO, 3mM 
glutamate and DEVD-CHO (50|iM) alone or in combination with 3mM glutamate. 
The percentage o f cell death was observed following 18 hours treatment with 
glutamate using LDH cytotoxicity assay as described in Materials and Methods. 
Comparison o f means were made using a one way ANOVA followed by a Dunnett’s 
post hoc, n s = not significant versus glutamate treatment alone, n = 4.
124
ra 30
Figure 4.9 Initiator caspases enhance glutamate induced cell death.
HT-22 cells were untreated, exposed to 0.1% milli Q, 0.1% DMSO, 3mM glutamate 
and lETD-CHO (50pM, caspase-8 inhibitor) or LEHD-CHO (50pM, caspase-9 
inhibitor) alone or in combination with 3mM glutamate. The percentage o f cell death 
was observed following 18 hours treatment with glutamate using LDH cytotoxicity 
assay as described in Materials and Methods. Comparison of means were made using 
a one way ANOVA followed by a Dunnett’s post hoc, ns = not significant, ** = 
p<0.01, *** = p<0.001 versus glutamate treatment alone, n = 4.
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4.5 DEVDase activity in glutamate treated cells
Despite the lack o f significant changes when caspase inhibitors were applied to 
glutamate treated cells, the possibility o f caspase activation during glutamate induced 
cell death could not be ruled out. Figure 4.10 shows the presence o f cleaved caspase- 
3 during glutamate induced cell death in HT-22 cells. A small increase was observed 
following an 18 hour incubation with 3mM glutamate, however this was not 
significant. DEVDase activity was monitored in glutamate and staurosporine treated 
cells however, no DEVDase activity was observed in glutamate treated cells (Figure 
4.11). Figure 4.12 shows that following exposure to glutamate, cells expressing 
pFRET-Casp3 do not result in a loss o f FRET, confirming the lack o f DEVDase 
activity.
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Figure 4.10 Glutamate induces no significant increase in cleaved caspase-3.
HT-22 cells were either untreated or exposed to 0.3% milliQ, 3mM glutamate, 0.1% 
DMSO or IpM  staurosporine for 18 hours. Fixed cells (formaldehyde) were then 
stained with PE conjugated anti-active caspase-3 and analysed by flow cytometry as 
described in materials and methods. High fluorescence levels were associated with 
the presence o f cleaved caspase-3 and the percentage of these regions is represented 
above. Comparison o f means were made using a one way ANOVA followed by a 
Bonferroni's post hoc, ns = not significant versus control, n = 4.
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Figure 4.11 Glutamate treatment does not induce DEVDase activity.
HT-22 cells were untreated, exposed to 0.1% milli Q water (control) and 3mM 
glutamate for 24 hours and 0.1 % DMSO or luM Staurosporine for 18 hours. The 
percentage of DEVDase activity in cell lysates was observed using DEVD-afc assay 
as described in Materials and Methods.
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Figure 4.12 Glutamate treatment does not induce FRET construct cleavage.
HT-22 cells transfected with pFRET-Casp3 in 25cm^ flasks were incubated for 72 
hours before being re-seeded onto poly-L-lysine treated coverslips. Cells remained 
untreated (A), or treated with 1% milli Q water (B), lOmM glutamate (C), 0.1% 
DMSO (D) or IpM  staurosporine (E) for 18 hours. Live cells were viewed using 
confocal microscopy at an excitation o f 488nm. Green fluorescence represents 
emission <545nm, red fluorescence represents emission >545nm. Figure shows 
representative results o f >3 experiments.
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4.6 The Role of Autophagy in Oxidative Glutamate Toxicity
As oxidative glutamate toxicity did not involve DEVDase activity the possible 
involvement o f an autophagic mechanism was next investigated. The autophagy 
inhibitor wortmannin enhanced glutamate induced cell death at 18 hours (see Figure 
4.13).
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Figure 4.13 Wortmannin enhances glutamate induced cell death
HT22 cells were untreated treated with 0.3% milliQ, 3mM glutamate or pre-incubated 
for 2 hours with 0.1% DMSO or lOOnM wortmannin prior to 3mM glutamate 
treatment. The percentage o f cell death was observed following 18 hours treatment 
with glutamate using LDH cytotoxicity assay as described in Materials and Methods. 
Comparison o f means were made using a one way ANOVA followed by a 
Bonferroni's post hoc, *** = p<0.001 ns = not significant versus glutamate treatment 
alone, n = 4.
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4.7 Calpain and cathepsin involvement in oxidative 
glutamate toxicity
Having ascertained a lack o f caspase involvement in glutamate induced cell death, the 
role o f other cell death associated proteases was investigated. Z-FA-FMK was used 
as a negative control to test for the sensitivity o f the FMK moiety present on the 
caspase inhibitor Z-VAD-FMK. Z-FA-FMK has previously been used as an inhibitor 
o f non-caspase proteases such as cathepsin B and although some reports suggest Z- 
FA-FMK also inhibits caspases (Lopez-Hemandez et al. 2003) previous work from 
this lab has never confimied this (Macanas-Pirard et al. 2005). Figure 4.14 shows that 
upon pre-treatment o f HT-22 cells with Z-FA-FMK glutamate induced cell death was 
almost completely abrogated over 24 hours. To investigate flirther the roles of 
calpains and cathepsins in glutamate mediated cell death, the more specific inhibitors 
ALLN and CA-074 Me were applied to the cells prior to glutamate treatment. Figure 
4.15 shows pre-treatment with ALLN, a calpain inhibitor abrogates cell death to a 
similar level observed by Z-FA-FMK. However the cathepsin B inhibitor CA-074 Me 
only showed a small, but significant, inhibition o f 3mM glutamate induced cell death 
at 18 hours (Figure 4.16).
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Figure 4.14 Z-FA-fmk inhibits glutamate induced cell death.
HT-22 cells were untreated, exposed to 0.1% milli Q water, 3 or lOmM glutamate, 
50pM Z-FA-fmk alone or in combination with 3 or lOmM glutamate. The percentage 
o f cell death was observed following 18 hours treatment with glutamate using LDH 
cytotoxicity assay as described in Materials and Methods. Comparison o f means were 
made using a one way ANOVA followed by a Bonferroni's post hoc, *** = p<0.001 
versus glutamate treatment alone, n = 4.
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Figure 4.15 The calpain inhibitor ALLN inhibits glutamate induced cell death.
HT-22 cells were untreated, exposed to 0.1% milli Q water (control), 3 or lOmM 
glutamate, lOpM ALLN alone or in combination with 3 or lOmM glutamate. The 
percentage of cell death was observed following 18 hours treatment with glutamate 
using LDH cytotoxicity assay as described in Materials and Methods. Comparison of 
means were made using a one way ANOVA followed by a Bonferroni's post hoc, *** 
= p<0.001 versus glutamate treatment alone, n = 4.
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Figure 4.16 The cathepsin B inhibitor CA-074 inhibits low glutamate induced cell 
death.
HT-22 cells were untreated, exposed to 0.1% milli Q water (control), 3 and lOmM 
glutamate, lOpM CA-074 alone or in combination with 3/lOmM glutamate. The 
percentage o f cell death was observed following 18 hours treatment with glutamate 
using LDH cytotoxicity assay as described in Materials and Methods. Comparison of 
means were made using a one way ANOVA followed by a Bonferroni's post hoc, * = 
p<0.05, ns = not significant versus glutamate treatment alone, n = 4.
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4.8 Calpain activity in glutamate treated HT-22 cells
Calpains are calcium dependent proteases therefore if calpain inhibition could limit 
cell death, so too should the limitation o f calcium ions (Ca^ *^ ). A concentration of the 
calcium chelator EOT A equal to that of the Ca^* in the media (1.9mM) inhibited 
glutamate induced cell death in HT-22 cells (Figure 4.17). Furthermore western blot 
analysis o f protein extracts from glutamate treated cells revealed the presence of a 
calpain cleaved fragment at ~150kDa lacking the caspase-3 cleavage band at 120kDa 
(Figure 4.18) and finally measurement o f calpain activity in glutamate treated HT22 
cells revealed high calpain activity at 6 hours post exposure (Figure 4.17).
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Figure 4.17 EGTA inhibits glutamate induced cell death.
HT-22 cells were untreated, exposed to 0.1% milli Q water, 0.05% PBS, 3 and lOmM 
glutamate, 1.9mM EGTA alone or in combination with 3 or lOmM glutamate. The 
percentage o f cell death was observed following 18 hours treatment with glutamate 
using LDH cytotoxicity assay as described in Materials and Methods. Comparison of 
means were made using a one way ANOVA followed by a Bonferroni's post hoc, ** = 
p<0.01, *** = p<0.001 versus glutamate treatment alone, n = 4.
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Figure 4.18 Glutamate induces calpain activity in HT22 cells
A, Whole cell lysates taken following 18 hours exposure to 0.1% DMSO, IpM 
staurosporine 1% milHQ or lOmM glutamate or untreated, were subjected to 6.5% 
SDS PAGE followed by ECL detection. Staurosporine induces caspase-3 (p i50 & 
p i20) and calpain (p i50) fodrin fragments whereas glutamate induces the calpain 
fragment only. B, HT22 cells exposed to 3, 5 or lOmM glutamate, 1% milHQ water 
or no treatment were trypsinised and the release o f free fluorescent AMC by cleavage 
o f the calpain substrate Suc-LLVY-AMC was monitored in whole cell aliquots over 2 
hours.
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Summary: Chapter 4
This chapter investigated the role o f death associated proteases in HT22 cells. 
Unusually a protective role was found for caspases which upon inhibition enhanced 
glutamate toxicity. Upon fiirther investigation this was found to be due to initiator 
caspases such as caspases 8 and 9. Although no role was found for caspase-3 in 
glutamate induced cell death, studies using the caspase-3 FRET construct (pFRET- 
Casp3) revealed that where no DEVDase activity can be detected, the FRET construct 
will not be cleaved, even in the presence o f other active proteases such as calpains.
The contributing death associated protease was identified as calpains although the role 
of other alternative proteases has yet to be mled out. The role o f calpains was 
confirmed not only by inhibition studies but also by enzyme activity assays and 
western blotting.
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5 THE ROLE OF KINASES IN OXIDATIVE 
GLUTAMATE TOXICITY
138
Introduction: Chapter 5
This final chapter investigates the role o f MAP kinases on glutamate induced 
oxidative toxicity. Previous work revealed that glutamate toxicity was dependent on 
activation o f extracellular related kinase (ERK) (Satoh et al. 2000; Stanciu et al. 2000; 
Stanciu and DeFranco 2002; Levinthal and Defranco 2004) which is usually 
associated with cell division (Zhang and Liu 2002). This chapter sets out to 
investigate whether the stress associated MAP kinase jun N-terminal amino kinase 
(JNK) is involved and identify a possible mechanism.
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5.1 Protein synthesis requirements of glutamate induced cell 
death.
In order to compare our system to previously described models of glutamate induced 
cell death we determined whether cell death could be limited by the addition o f the 
protein synthesis inhibitor cycloheximide. Figure 5.1 shows that Ipg/ml 
cycloheximide inhibits glutamate induced cell death.
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Figure 5.1 Cycloheximide inhibits glutamate induced cell death.
HT-22 cells were untreated or exposed to 0.1% milli Q water, 3 or lOmM glutamate, 
0.1% DMSO, Ipg/ml cycloheximide alone or in the presence o f 3 or lOmM 
glutamate. The percentage o f cell death was observed following 18 hours treatment 
with glutamate using LDH cytotoxicity assay as described in Materials and Methods. 
Comparison o f means were made using a one way ANOVA followed by a 
Bonferroni's Multiple Comparison post hoc, *** = p<0.001 versus glutamate, n = 4.
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5.2 The role of JNK in glutamate induced cell death.
Following previously published data which showed MAP kinases play a role in 
glutamate induced cell death (Schauwecker 2000; Stanciu and DeFranco 2002; 
Bogoyevitch et al. 2004), we determined whether inliibition o f the jun-N tenninal 
amino kinase (JNK) would have any affect on glutamate induced HT22 cell death. 
Figure 5.2 shows that SP600125 significantly inhibits glutamate cell death. 
Furthermore this had no effect on cytochrome c localisation (Figure 5.3), however, 
nuclear morphology was dramatically affected (Figure 5.4). Figure 5.4 shows the 
presence o f SP600125 results in abnormally large and lobed nuclear stmctures which 
appear to be the result o f an increase in DNA synthesis as shown by flow cytometry 
(Figure 5.5). The negative control for SP600125 which contains an extra methyl 
group was used to show the effects o f SP600125 were due to its ability to inliibit 
enzyme activity (Bennett et al. 2001) (Figure 5.6).
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Figure 5.2 The JNK inhibitor SP600125 inhibits glutamate toxicity.
HT-22 cells were untreated or exposed to 0.1% milli Q water, 3 or lOmM glutamate, 
1% DMSO, 15pM SP600125 alone or in the presence of 3 or lOmM glutamate. The 
percentage o f cell death was observed following 18 hours treatment with glutamate 
using LDH cytotoxicity assay as described in Materials and Methods. Comparison of 
means were made using a one way ANOVA followed by a Bonferroni's Multiple 
Comparison post hoc, *** = p<0.001 versus glutamate, n = 4.
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Figure 5.3 SP600125 has no effect on cytochrome c localisation.
HT-22 cells were exposed to 0.3% milli Q water (A), 3mM glutamate (B) and 15uM 
SP600125 in the absence (C) or presence (D) of glutamate. Cells were incubated for 
18 hours before being fixed (4% paraformaldehyde) and stained with anti-cytochrome 
c antibody and FITC conjugated secondary antibody. Scale bars represent 20pm. 
Figure shows representative results o f >3 experiments.
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Figure 5.4 SP600125 alters nuclear morphology.
Fixed cells (4% formaldehyde) previously untreated (A), treated for 18 hours with 
0.3% milHQ water (B), 3mM glutamate (C), 1% DMSO (D), 15uM SP600125 alone 
(E) or in combination with 3mM glutamate were stained with 2pg/ml o f the nuclear 
dye Hoechst 33258 and viewed under uv optics using epifluorescence microscopy. 
Figure shows representative results o f >3 experiments.
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Figure 5.5 SP600125 promotes cell cycle arrest in G2
Fixed cells (70% ethanol) previously untreated (A), treated for 18 hours with 1% 
milliQ water (B), 1% DMSO (C), 15pM SP600125 (D), lOmM glutamate (E) or 
15pM SP600125 + lOmM glutamate (F) were stained with propidium iodide and 
analysed by flow cytometry. The left hand peak represents those cells with one set of 
DNA in the G1 phase of the cell cycle (as gated by region ‘E ’), the right hand peak 
represents those cells with two sets o f DNA in the G2 phase o f the cell cycle.
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Figure 5.6 SP600125 negative control does not affect glutamate induced cell 
death.
HT-22 cells were untreated or exposed to 0.1% milli Q water, 3 or lOmM glutamate, 
1% DMSO, 15pM SP600125 negative control alone or in the presence o f 3 or lOmM 
glutamate. The percentage o f cell death was observed following 18 hours treatment 
with glutamate using LDH cytotoxicity assay as described in Materials and Methods. 
Comparison o f means were made using a one way ANOVA followed by a 
Bonferroni's Multiple Comparison post hoc, ns = not significant versus glutamate, n = 
4.
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5.3 The role of GSK3P in glutamate induced cell death.
Following the observation that the stress activated MAP kinase JNK appeared to play 
a role in glutamate toxicity and the cell cycle, the involvement o f glycogen synthase 
kinase 3(3 (GSK3(3) was also investigated. GSK3P has been shown to be involved in 
the MAP kinase pathways (Frame and Cohen 2001) and oxidative glutamate induced 
cell death (Schafer et al. 2004). Figure 5.7 shows SB415286 limits glutamate induced 
toxicity and this also appears to be linked to an increase in G2 cell cycle arrest (Figure 
5.9). Enlargement o f nuclei were apparent following GSK3P inhibition (Figure 5.8) 
similar to that found with JNK inhibition (Figure 5.4).
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Figure 5.7 The GSK3(3 inhibitor SB415286 inhibits oxidative cell death.
HT-22 cells were untreated or exposed to 0.1% milli Q water, 3 or lOmM glutamate, 
0.1% DMSO, 25pM SB415286 alone or in the presence o f 3/lOmM glutamate. The 
percentage o f cell death was observed following 18 hours treatment with glutamate 
using LDH cytotoxicity assay as described in Materials and Methods. Comparison of 
means were made using a one way ANOVA followed by a Bonferroni's Multiple 
Comparison post hoc, *** = p<0.001 versus glutamate, n = 4.
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Figure 5.8 SB415286 induces enlarged nuclear morphology
HT-22 cells were exposed to 0.1%DMSO (A), 25pM SB415286 (B) glutamate (C) or 
glutamate + SB415286 (D). Cells were incubated for 18 hours before being fixed 
(4% formaldehyde) and stained with draq5 chromatin dye. Scale bars represent 
20pm. Figure shows representative results o f >3 experiments.
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Figure 5.9 GSK3P inhibitor promotes G2 cell cycle arrest
Fixed ceils (70% ethanol) previously untreated (A), treated for 18 hours with 1% 
milliQ water (B), 1% DMSO (C), 25|iM SB415286 (D), lOmM glutamate (E) or 
25|iM SB415286 + lOmM glutamate (F) were stained with propidium iodide and 
analysed by flow cytometry.
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5.4 Quantification of cell cycle shifts.
The cuiTent work in this chapter suggested that inhibitors that were able to limit 
glutamate induced cell death also affected the normal cell cycle. It was next 
determined whether previous inhibitors affected the cell cycle in the same way. 
Figure 5.10 shows that glutamate induces an increase in G2 population. Statistical 
analysis canied out on samples where n > 3 revealed significant increases in G2 
populations following treatment with SP600125 and ALLN but not z-VAD-finlc 
(Figure 5.11).
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Figure 5.10 Glutamate induces an increase in G2 population
Fixed cells (70% ethanol) previously treated for 18 hours with 0.5% milli Q water 
(A), 5mM glutamate (B), 0.1% milli Q water (C) or lOmM glutamate (D) were 
stained with propidium iodide and analysed by flow cytometry. Histograms were then 
analysed using ‘Multicycle for windows’ software. Figure shows representative 
results o f >3 experiments.
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Figure 5.11 SP600125 and ALLN induce significant increases in G2.
Fixed cells (70% ethanol) previously treated for 18 hours with 0.3% milliQ, 1 or 0.1% 
DMSO, 15pM SP600125, 50pM z-FA-fmk, lOpM ALLN in the presence or absence 
o f 3mM glutamate were stained with propidium iodide and analysed by flow 
cytometry. Histograms were then analysed using ‘Multicycle for windows’ software 
and the percentage of cells within the G2 fraction are represented above. Comparison 
of means were made using a one way ANOVA followed by a Bonferroni's Multiple 
Comparison post hoc, *** = p<0.001 ** = p<0.01 ns = not significant versus 
glutamate; ### = p<0.001, # = p<0.05, NS = not significant versus DMSO control, n 
> 3 .
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5.5 Glutamate toxicity and cell cycle progression.
Flow cytometry data indicated a possible role for cell cycle progression in glutamate 
toxicity. This was investigated by studying the effects o f serum withdrawal prior to 
glutamate treatment and thereby inliibiting cellular proliferation. Figure 5.12 shows a 
significant reduction in glutamate toxicity when cells were incubated in progressively 
lower levels o f serum. Previous data from LDH cytotoxicity assays was then 
analysed to give a relative level o f cell growth following treatment with previously 
used inhibitors with or without glutamate treatment. Figure 5.13 shows that out o f 5 
inliibitors that inhibited cell death, three o f these inhibited cellular proliferation. 
These were SP600125, the inhibitor o f JNK, cycloheximide, a protein synthesis 
inhibitor and ALLN a calpain inhibitor. Two other cytoprotective agents SB415286, 
a GSK3p inhibitor, and (3-estradiol, an antioxidant, did not affect cell cycle 
progression.
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Figure 5.12 A reduction in serum concentrations correlates with a reduction in 
glutamate toxicity.
HT-22 cells were pre-incubated in 0.5 to 10% serum for 24 hours before being treated 
with 3 or lOmM glutamate or milli Q controls. The percentage o f cell death was 
observed following 18 hours treatment using LDH cytotoxicity assay as described in 
Materials and Methods. Comparison o f means were made using a one way ANOVA 
followed by a Bonferroni's Multiple Comparison post hoc, *** = p<0.001 versus 10% 
serum, n = 4.
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Figure 5.13 Cycloheximide, SP600125 and ALLN inhibit cell cycle progression.
HT-22 cells seeded at 8,000 cells/well were treated with lOj.iM (3-estradiol, Ipg/m l 
cycloheximide lOpM ALLN, 15pM SP600125 or 25pM SP415286 with or without 3 
or lOmM glutamate for 24 hours. The relative cell number remaining after 24 hours 
was determined by treatment with Triton and assayed for LDH activity as described in 
materials and methods. Comparison o f means were made using a one way ANOVA 
followed by a Dunnet’s post hoc, *** = p<0.001 versus vector control (ethanol or 
DMSO), 11 = 4.
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Summary: Chapter 5
This final chapter aimed to identify a possible role for the stress associated MAP 
kinase JNK. In doing so unusual nuclear morphology was noticed which led to the 
investigation of DNA content and eventually cell cycle progression. Having 
identified that JNK appeared to protect cells from glutamate induced toxicity by 
preventing progression from the G2 phase o f the cell cycle, it was then determined 
whether other inhibitors known to limit cell death affected the cell cycle in the same 
way. Similar G2 blocks were observed from calpain inhibition (ALLN) and GSK 
inhibition (SB415286).
To determine how important cell cycle progression was to glutamate toxicity, serum 
reduction was used to inhibit cell cycle progression which, led to an inhibition o f cell 
death. The previously used inhibitors were then assessed for their action on the cell 
cycle which proved that cycloheximide, ALLN and SP600125 inhibited cell cycle 
progression which may account for their ability to inhibit glutamate induced toxicity. 
The fact that SB415286 did not inhibit cell cycle progression alone but did in 
combination with glutamate suggested that GSK may be one o f the proteins linking 
the cell cycle to cell death but this would have to be investigated further.
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6 DISCUSSION
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6.1 Chapter 3 Discussion
The role o f apoptosis in ischaemic insults has been shown to involve cytochrome c 
release, Bax translocation, chromatin condensation (Fujimura et al. 1998; Cao et al. 
2001; Northington et al. 2001). Although excitotoxicity may explain much of the 
initial damage, both apoptotic and necrotic, the delayed apoptotic damage has been 
proposed to be mediated through the CD95 death receptor pathway (Martin-Villalba 
et al. 1999; Rosenbaum et al. 2000; Jin et al. 2001). The molecular mechanisms of 
CD95 induced neuronal death have yet to be studied in detail due to the lack o f a 
suitable model system. This chapter set out to characterise CD95 induced cell death 
in the murine hippocampal HT22 cell line and to detect caspase-3 activity using a 
novel FRET construct.
6.1.1 CD95 induced apoptosis
Cell death was induced in HT22 cells using the Jo2 hamster anti-CD95 antibody 
(Yonehara et al. 1989). HT22 cells, like some other cell lines (Fulda et al. 2000), 
required sensitisation to anti-CD95 induced apoptosis with the protein synthesis 
inhibitor cycloheximide, suggesting a low caspase-8 activity at the DISC, or an 
increased abundance of inhibitory apoptotic proteins. As with staurosporine, anti- 
CD95 antibody resulted in the condensation o f nuclei compared to DMSO and 
cycloheximide treated cells as shown with Hoechst staining. Cell death induced by 
anti-CD95 antibody and cycloheximide was relatively slow compared to the induction 
o f cell death upon exposure to staurosporine. Despite this upon exposure to a higher 
concentration o f anti-CD95 antibody, no increase in cell death was observed (data not 
shown) indicating that the original concentrations used resulted in receptor saturation. 
The use o f between lOOng/ml and lOjiig/ml anti-CD95 antibody is an accepted
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concentration for activation o f CD95 death receptor pathways as described in 
previous studies (Jones et al. 1998; Yin et al. 1999).
The presence o f chromatin condensation may suggest caspase activity within anti- 
CD95 treated cells. Further investigation using caspase inhibitors showed a 
significant inhibition o f anti-CD95 antibody and staurosporine induced apoptosis 
indicating a dependence on caspase activity in both systems. The enhanced inhibition 
o f cell death using Q-VD-OPh compared to that o f z-VAD-FMK may be due to its 
enhanced membrane permeability owing to a methyl ester amino acid group (Caserta 
et al. 2003). This caspase inhibition data correlates with previous in vivo work using 
caspase inhibitors to limit the hippocampal cell death following cerebral ischaemia 
(Gillardon et al. 1999).
Despite the reported potency o f z-VAD-FMK in the inhibition o f anti-CD95 induced 
apoptosis, in most experimental models involving the CD95 death receptor pathway, 
cell death was inhibited by only 13% compared with samples without z-VAD-FMK 
which may reflect a proportion o f cell death to be caspase-independent. A similar 
investigation by Deas and co-workers (1998) showed that anti-CD2 and staurosporine 
induced apoptosis was not attenuated by the addition of z-VAD-FMK. Despite 
observed inhibition of caspases-3 and 7 in these cells, the persisting cell death was 
due to mitochondrial alterations (Deas et al. 1998), which may reflect a proportion of 
cell death persisting in the presence o f caspase inhibitors to be induced by a 
mitochondrial-induced caspase independent mechanism such as Bax mediated 
cytochrome c release (Xiang et al. 1996). More recently, using a caspase active site 
probe, Methot and co-workers (2004) showed that inhibition o f caspase-mediated
159
DNA fragmentation required up to 75% active site occupancy. This suggests that a 
persistent and high level o f caspase inhibition is required to suppress certain 
downstream events. In this system therefore the levels of caspase inhibition used may 
not be sufficient to block the caspase activity responsible for cell death.
The non-caspase protease inhibitor z-FA-fmk was used to test whether cysteine 
proteases other than caspases, contributed to CD95 induced cell death as z-VAD has 
been shown to also inhibit these proteases (Schotte et al. 1999). Data provided in this 
report demonstrated other proteases such as cathepsin B, previously shown to be 
inhibited by z-FA (Kingham and Pocock 2001), to be responsible for a percentage of 
cell death induced by anti-CD95 antibody + CHX but not CHX only. This suggests a 
role for cathepsins in CD95 induced apoptosis in HT22 cells. Cathepsin D has 
previously been shown to contribute to CD95 mediated cell death in hepatocytes 
(Deiss et al. 1996), furthermore it has been shown that transformed cells are sensitised 
to the lysosomal death pathway (Fehrenbacher et al. 2004) which may explain further 
the role o f cathepsins in CD95 mediated cell death in this immortalised cell line.
Further investigations into other proteins involved in anti-CD95 antibody induced 
apoptosis in HT22 cells failed to show a dependence on a variety o f molecules 
previously shown to play a role in CD95 mediated cell death. The MAP kinase p38 
has been shown to be activated via caspases following CD95 stimulation (Juo et al. 
1997) and its inhibition shown to inhibit CD95 induced cell death (Harper and 
LoGrasso 2001). Serine proteases inhibitors have previously been shown to reduce 
cell death and the use o f inhibitors at lower levels revealed serine protease activity 
was necessary for plasma membrane blebbing and DNA fragmentation (Weis et al.
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1995). The in the lack o f inhibition of cell death from serine protease inhibition this 
study may suggest that other proteases are contributing to features such as DNA 
hagmentation. PLA2 despite being activated following CD95 stimulation (Jaattela et 
al. 1995) has also been shown to be dispensable as a pro-apoptotic agent in CD95 
mediated apoptosis in other cell lines (Enari et al, 1996) which may reflect the data 
observed here where CD95 mediated apoptosis was not affected by the addition of 
dexamethasone. Lithium has many actions within the cell, one of them the inhibition 
o f glycogen synthase kinase-3. The addition o f lithium has been shown in CD95 
mediated apoptosis to be pro-apoptotic (Song et al. 2004) via the inhibition of 
glycogen synthase kinase-3. The results here may be due to the high levels o f cell 
death achieved with anti-CD95 antibody which may mask any affects from lithium. 
A lower level of anti-CD95 antibody may more clearly show any enhanced apoptosis 
due to the addition of lithium.
Cyclosporine A has previously been used as a blocker o f the mitochondrial 
permeability transition pore (Tafani et al. 2002). The failure of cyclosporine A in this 
system to inhibit CD95 mediated cell death suggests that involvement of the 
permeability transition pore is not the primary event leading to cytochrome c release. 
Suramin has also been used previously to identity pathway types in CD95 mediated 
cell death (Eichhorst et al. 2004), where suramin inhibited the apoptotic effects of 
anti-CD95 antibody in type II cells. Interestingly, cells in this study by Eichhorst et 
al, which required sensitisation with CHX were susceptible to suramin induced cell 
death as found in here where 250pM suramin was toxic to HT22 cells alone.
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Previous data has demonstrated that HT22 cells contain no functional oestrogen 
receptors (Green et al. 1998). A receptor inducible concentration of p-estradiol that 
did not exert antioxidant effects, had no effect on CD95 mediated cell death in HT22 
cells which had previously been shown to induce alterations in Bcl-2/Bax ratios to 
protect cells (Huber et al. 1999). P-estradiol can also be used as an antioxidant 
however, pM concentrations of p-estradiol did not affect CD95 mediated cell death 
indicating that the mechanism did not depend on oxidative stress.
The translocation o f cytochrome c from the mitochondria to the cytosol has been 
observed in animal models o f ischaemia (Fujimura et al. 1998; Zhao et al. 2003) and 
was also observed here in HT22 cells following CD95 stimulation. The extent of 
cytochrome c release has previously been shown to involve total release from the 
mitochondria in individual cells (Goldstein et al. 2000). The Western blot data 
presented here shows a proportion o f cytochrome c remaining in the mitochondrial 
fractions (fig. 3b). Although this may represent a partial loss o f c}4ochrome c from 
the mitochondria it may also represent a population of cells that do not undergo cell 
death, as even after 48 hours exposure to anti-CD95 antibody and cycloheximide, a 
maximum of 74% cell death was achieved. Further evidence for the complete loss of 
cytochrome c was shown using dual staining o f c)4ochrome c and nuclei, where 
selected nuclear staining revealed no cytochrome c present in the cell. The flow 
cytometry technique o f analysing cytochrome c release showed cytochrome c release 
to an even lesser extent than western blot results. This may reflect differences in the 
techniques used. During permeabilisation to release c)4osolic proteins, western 
blotting samples were incubated for 2 minutes followed by centi'ifugation in 
permeabilisation buffer and those for flow cytometry were incubated for 2 minutes
162
before being fixed. This technique may require further optimisation to wash the cells 
in a greater volume o f permeabilisation buffer for longer periods of time thereby 
releasing cytosolic proteins.
The mitochondrial release of cytochrome c has previously been proposed to be 
initiated by the pro-apoptotic protein Bax (Scorrano and Korsmeyer 2003) which may 
be one o f the upstream initiators o f c)/tochrome c release following cerebral ischaemia 
(Cao et al. 2001; Zhao et al. 2003). In that study Bax was observed to undergo two 
events which have previously been shown to be vital to Bax initiated cytochrome c 
release: (i) activation via a conformational change (Desagher et al. 1999) and (ii) 
translocation to the mitochondria (Eskes et al. 2000). Immunocytochemistry 
techniques here revealed no difference in the extent o f Bax localisation in apoptotic 
and healthy HT22 cells which may reflect a proportion o f Bax loosely associated to 
cellular membranes. However, Western blotting revealed a significant change in Bax 
localisation following CD95 antibody stimulation.
6.1.2 FRET Construct Development
The use o f fluorescence resonance energy transfer (FRET) as a ‘spectroscopic ruler", 
described by Stryer in 1978 (Stryer 1978), has recently led to the production o f a 
number o f FRET based protein constructs to look at the in situ activation of cellular 
enzymes (Harpur et al. 2001; Morgan and Thorburn 2001; Nishii et al. 2002; Onuki et 
al. 2002; Rehm et al. 2002; Luo et al. 2003; Takemoto et al. 2003). Previous FRET 
based systems utilising the DEVD cleavage site have shown that DEVD-FRET based 
constructs, although predominantly cleaved by caspase-3, are also cleaved by 
caspases 6, 7, 8 and 9 (Rehm et al. 2002; Takemoto et al. 2003). However Takemoto
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and co-workers used caspase-3 deficient apoptotic cell lysates to show only a small 
proportion o f their DEVD construct was cleaved, indicating that most of the DEVD- 
FRET cleavage was done by caspase-3 (Takemoto et al. 2003). This conclusion is 
most likely applicable to the present study too, since the loss of FRET correlated with 
the appearance of active caspase-3, shown by flow cytometi ic techniques. Yet, FRET 
based identification o f caspase-3 activity was considerably enhanced compared to the 
detection o f the p i 7/20 fragments. This may reflect the catalytic nature o f the caspase 
compared to the actual o f active caspase. Flowever, the participation o f upstream 
caspases involved in the FRET construct cleavage process cannot yet be ruled out.
6.2 Chapter 4 Discussion
Glutamate induced oxidative stress via glutathione depletion has been modelled in 
immature primary cortical neurons (Murphy et al. 1989) and the HT22 cell line (Davis 
and Maher 1994) both models chosen for their lack of glutamate receptors. This 
study has continued to investigate the molecular mechanisms associated with 
oxidative glutamate toxicity in the HT22 cell line, specifically to identify the role of 
death associated proteases in oxidative glutamate toxicity.
Previous studies have shown that glutamate induces cell death in HT22 cells with an 
ECso of 3-5mM (Davis and Maher 1994; Tan et al. 1998b) a value which was 
confirmed in this study. Inhibition of cell death with antioxidant levels o f p-estradiol 
indicated the oxidative nature o f cell death. Investigation into the morphology of 
dying HT22 cells by Tan and co workers (2001) utilised electron microscopy to 
analyse cells and did not reveal any classical chromatin condensation or 
fragmentation. In this study we have used the nuclear dye Hoechst 33258 to reveal
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chromatin condensation which was further confirmed by confocal analysis with the 
nuclear dye draqS. The discrepancies between the data observed here and those 
electron microscopy images observed by Tan et al are not unusual. As discussed 
above, in a similar model of cell death Bezvenyuk and co workers (2003) showed that 
the chromatin condensation observed by Hoechst staining was not always a reflection 
o f the classic chromatin fragmentation as observed by electron microscopy. This 
apparent difference in results may explain this model system where partial chromatin 
condensation, detectable by nuclear staining only, is observed. Other classical signs 
o f apoptosis were also not present in this model system such as cjTochrome c release 
supporting previous observations (Tan et al. 2001). Detection o f extracellular 
phosphatidyl serine by annexin V (AV) and propidium iodide (PI) did not appear to 
show a positive translocation o f AV prior to PI uptake indicating that phosphatidyl 
serine translocation is not a feature o f oxidative glutamate toxicity. These initial 
investigations in to glutamate induced cell death reveal a morphology that does not 
reflect a typical necrotic or apoptotic phenot}'pe.
Wortmannin has previously been used as an inhibitor of autophagy (Shimizu et al.
2004). As this system did not appear to be classic apoptosis or necrosis this inhibitor 
was used to asses a role for autophagy in oxidative glutamate toxicity. A small 
enhancement revealed no deteriorative role for autophagy but possibly a protective 
one. This observation would concur with the normal role for autophagy; to remove 
damaged organelles or structures that would otherwise damage the cell. Further work 
would be required to confirm the presence o f autophagy in this system and the extent 
o f its role in this system.
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6.2.1 The Role of Caspases in Oxidative Toxicity
Initial studies investigating pan-caspase inhibition in oxidative glutamate toxicit)' 
revealed that caspase inhibition limited cell death (Stanciu and DeFranco 2002), an 
effect which was not observed in this study or other later studies (van Leyen et al.
2005). This investigation revealed that Z-VAD-FMK enhanced glutamate toxicity in 
HT22 cells. Although this has not previously been observed in neuronal cells, Z- 
VAD-FMK enhancement o f cell death has been observed in other ROS mediated cell 
death models (Vercammen et al. 1998; Kim and Han 2001; Cauwels et al. 2003; Liu 
et al. 2003). It has been suggested that the enhancement incurred by this broad range 
caspase inhibitor may be due in part to the cleavage o f ROS producing species by 
caspases such as RIP and PLA? (Cauwels et al. 2003; Chipuk and Green 2005). 
Furthermore it has been proposed that damaged, ROS producing mitochondria are 
removed by active caspases thereby protecting the cell (Fiers et al. 1999). However, 
in the presence o f z-VAD these mitochondria remain, producing more ROS (Fiers et 
al. 1999). As glutamate induced toxicity in this model is thought to occur by 
increased ROS (due to reduced glutathione), increased cell death observed by caspase 
inhibition may be due to sustained ROS production. Indeed, similar nuclear 
morphology was noted upon the addition of z-VAD which may indicate that oxidative 
toxicity contributed to cell death in both systems.
Although van Leyen and co-workers did not find a protective effect from Z-VAD- 
FMK, neither did they find an enhancement o f cell death. However, the levels of 
glutamate at such a late stage used in the study by van Leyen et al (2005) showed that 
cytotoxicit}' was already near maximal therefore, an enhancement by Z-VAD-FMK 
would be difficult to observe. Indeed, work here shows that where glutamate toxicity
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alone was >70%, the observed enhancement from Z-VAD-FMK was reduced. 
Therefore, it can be proposed that the lack o f enhancement in the van Leyen study 
may have been due to the high levels o f glutamate used.
Use o f the non-caspase protease inhibitor Z-FA-FMK suggested that caspases were 
the proteases responsible for the enhancement o f cell death. Further investigation 
using selective caspase inhibitors, showed that caspase-9 and, to a lesser extent, 
caspase-8 inhibition resulted in enhancement o f glutamate induced cell death. This 
suggests that in this system caspases 8 and 9 may be responsible for the cleavage and 
inactivation o f ROS producing species. One o f the proteins thought to be responsible 
for ROS production, PLA2, although predominantly cleaved by caspase-3 has also 
been shown to be cleaved by caspase-8 (Adam-Klages et al. 1998). Evidence for an 
anti-apoptotic role for caspase-9 has also been observed in B-cells where an LEHD 
based inhibitor and more specifically RNA interference enhanced staurosporine 
induced cell death (Shah et al. 2004).
Increased activity o f caspase-9 is associated with cytochrome c release. As no release 
o f cytochrome c was observed in this system another mechanism may be responsible 
for its activation if activity is found here. Caspase-9 has been shown to be directly 
activated by ROS (Kim and Park 2003) without mitochondrial involvement (Kim and 
Park 2003; Katoh et al. 2004). It is therefore likely that caspase-9 activation occurs 
following ROS production possibly acting to limit further ROS production and reduce 
cell damage.
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Interestingly, previous work has shown that inhibition o f caspases by Z-VAD-FMK 
has been shown to inhibit cell cycle progression in B cells (Kennedy et al. 1999; 
Luschen et al. 2000). Inhibition o f cell cycle in this system by serum withdrawal later 
showed cell cycle inhibition to be protective (Figure 5.12). This suggests that rather 
than cell cycle inhibition, the enhanced cell death observed from caspase inhibition in 
this system reflects a cytoprotective effect for caspases such as caspases-8 and -9.
Caspases 8 and 9 are initiator caspases and their activit)' is usually associated with the 
activation of downstream effector caspases such as caspase-3. Inhibition studies with 
Ac-DEVD-CHO did not affect glutamate induced toxicity and further studies with the 
DEVD FRET construct did not reveal DEVDase activity in glutamate treated cells. 
Fodrin cleavage confirmed this lack of caspase-3 (DEVDase) activity as well as 
showing calpain activity. Altogether this data proves a lack o f effector caspase 
activity within glutamate treated HT22 cells. Furthermore, the knowledge that 
glutamate treated cells utilised a protease other than caspase-3 provided evidence that 
the FRET construct is a reliable detector for specifically caspase-3 like activity and is 
not affected by calpain activity.
6.2.2 The Role of Calpains in Oxidative Toxicity
Non-caspase mediated effects of Z-VAD-FMK are often eliminated by the use of the 
non-caspase protease inhibitor Z-FA-FMK (Scliotte et al. 1999). The near complete 
inhibition offered by Z-FA-FMK in this system indicated that other proteases 
contributed to the cell demise, whereas caspases appear to contribute to cell survival. 
This was confirmed by inhibition by the calpain inhibitor ALLN. ALLN is also a 
proteosome inhibitor and similar proteosome inhibitors have already been shown to
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limit glutamate mediated toxicity^ in HT22 cells (van Leyen et al. 2005). Furthermore 
within the same study calpain inhibitor III did not inhibit glutamate induced toxicily. 
Therefore to verify the involvement o f calpains in glutamate induced oxidative stress 
we looked at the downstream effects of calpain activity as well as monitoring the 
activity of calpains within living cells. Calpain activity was observed 6 hours 
following glutamate exposure with little or no activity observed at 3hrs and 18hrs. 
Interesting, the activity o f calpains appears to be constant for all three of the 
concentrations tested (3-1 OmM) which may indicate an ‘all or nothing’ response 
however, this will require further investigation. The loss o f calpain activity at 18hrs 
may indicate calpain breakdown or the loss o f the cell membrane integrity and 
therefore the loss o f calpains from the cell. Further conformation for the involvement 
of calpains in glutamate toxicity came from western blotting o f the calpain target 
fodrin, which showed calpain cleaved fragments at 24hrs, and cytotoxicity studies 
using the calcium chelator EGTA, which inhibited cell death.
Many calpain inhibitors such as acetyl-Leu-Leu-nLeu aldehyde (ALLN) and 
benzyloxycarbonyl-Leu-Leu-nVal aldehyde (ZLLnVal) have also been shown to 
inhibit proteosome activity. In a comparison of the specificities of various 
calpain/proteosome inhibitors only ZLLnVal proved to have a similar EC50 with 
regards to proteasome inhibition and the actual proteasome inhibition curves for 
ALLN and other peptidyl protease inhibitors could not be obtained due to the 
inhibitors reaching saturation in the media (Mellgren 1997). Therefore the use of 
ALLN at low concentrations can be assumed to be predominantly inhibiting calpain 
activity over proteasome activity. However, the presence o f calpain activity does not
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necessarily rule out proteosome and/or cathepsin activity and therefore two pathways 
may be present.
Z-FA-FMK has been described as a negative control for caspase inhibitors such as Z- 
VAD-FMK (Jiang et al. 1999) and is used as an inhibitor of cathepsins B/L (Kingham 
and Pocock 2001), Unusually, despite almost complete inhibition with z-FA in this 
system, no inhibition was observed with the cathepsin inhibitor CA-074. This may 
reflect a certain level o f non-specificity o f the compound as, like z-VAD, it also 
contains an FMK group thought to contribute to the non-specificity of associated with 
Z-VAD-FMK (Schotte et al. 1999). Indeed, inhibition from the calpain inhibitor 
ALLN suggests that the inhibition observed from Z-FA-FMK may reflect an 
inhibition o f calpains and cathepsins B/L.
This chapter portrays oxidative glutamate toxicity in HT22 cells as cell death with 
features o f apoptotic and necrotic morphology in agreement with previous studies 
(Tan et al. 1998a). Autophagy along with caspases may contribute a protective role 
for damaged cells however, it is calpains that appear to contribute most to cell 
breakdown. Furthermore this chapter confinned the specificity of the DEVD FRET 
construct for caspase activity' opposed to calpains.
6.3 Chapter 5 Discussion
Oxidative glutamate toxicity' in HT22 cells has appeared to show a degenerative role 
for growth associated MAP kinases (Satoh et al. 2000; Stanciu et al. 2000; Levinthal 
and Defranco 2004). This final chapter set out to determine whether the stress
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associated MAP kinase JNK and another cellular kinase GSK, also played a role in 
oxidative stress in HT22 cells.
The activation o f JNK by ROS has been observed previously (Kamata et al. 2005), 
and is thought to be mediated by the oxidation and inactivation of JNK phosphatases 
and also the dimérisation and activation o f ASK l (Ichijo et al. 1997; Gotoh and 
Cooper 1998). The inhibition o f cell death by SP600125 observed in this study 
suggested JNK was active during oxidative glutamate damage, possibly activated by 
the increase in reactive oxygen species (ROS). Verification o f JNK specificity by use 
o f the negative control lessened the probability of artifactual data. The unexpected 
nuclear morphology observed from JNK inhibition, led to the investigation into 
DNA/cell cycle distribution. This then led to the finding that JNK inhibition results in 
an enlarged G2 population. Furthermore the similar increases in G2 sub populations 
with other inhibitors known to limit cell death, the calpain inhibitor ALLN (chapter 4) 
and the GSK inhibition (Schafer et al. 2004) provided further evidence that glutamate 
toxicity required progression through G2 resulting in mitotic cell death.
6.3.1 Neurotoxicity and the cell cycle
In this final chapter our model o f oxidative neuronal toxicity has provided evidence to 
suggest that HT22 cells must progress through the cell cycle into a mitotic cell death. 
However, it is well known that in vivo neurons are permanently differentiated and 
would not be expected to undergo the process o f cell division. However, recent 
evidence suggests that in neurodegenerative pathologies such as Alzheimer’s disease 
and ischaemia, neurones actually re-enter the cell cycle which then results in cell 
death (Katchanov et al. 2001; Raina et al. 2001 ; Love 2003a; Webber et al. 2005).
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At this point it is interesting to note that features o f apoptotic/dying cells often reflect 
similar features associated with cell division (King and Cidlowski 1995). Chromatin 
condensation is often a feature o f dying cells and is a requirement for chromatid 
separation during mitotic division. Bcl-2, an anti-apoptotic protein, the inactivation of 
which is often observed in cell death mechanisms is also required for progression 
through the cell cycle (Yamamoto et al. 1999).
6.3.L I  Cyclins and Cyclin dependent Idnases
Cyclins are a group o f proteins which contribute towards the progression o f the cell 
through the various phases o f the cell cycle. Cyclins occur as inactive phosphorylated 
proteins which activate specific cyclin dependent kinases (CDKs). Figure 6.1 shows 
the main cyclins involved in cell cycle progression and their stage o f activation.
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Figure 6.1: The contribution of cyclins to the cell cycle.
The majority o f cells if inactive remain in Go including post mitotic neurons. 
However those that progress through the cell cycle progress through each phase via 
activation o f proteins known as cyclins. Activation o f the apoptotic inducing protein 
p53 can arrest cells in G? and lead to apoptosis if cell damage is sufficient. Activation 
of another cell cycle regulatory protein p21 is regulated by c-jun. Once active p21 
inhibits the activation o f cyclin B and therefore progression from S/G? to G2/M 
(adapted from Cakir and Ballinger 2005).
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In a model o f DNA damage induced cell death in a neuronal cell line. Park and co­
workers (1997) showed that apoptosis could be inhibited via cyclin dependent kinase 
inhibitors or G l/S cell cycle blockers. This inhibition was not reproducible however 
with agents which did not lead to DNA damage such as serum withdrawal (Park et al. 
1997; Park et al. 1998) which suggested that DNA damage was a critical step in the 
induction o f cell cycle dependent cell death. Cyclin dependent kinase inhibition was 
also shown to be protective against proteasome inhibition induced cortical neuron cell 
death (Rideout et al. 2003). Cyclin dependent kinase activation has also been shown 
in mouse and rat models o f ischaemia (Timsit et al. 1999; Katchanov et al. 2001) as 
well as post mortem human samples (Love 2003b).
This evidence suggests that cyclin dependent kinases and cyclins, play a role in 
certain forms o f neuronal cell death in vitro and in vivo. In the model of 
neurodegeneration described in this study, it is likely that cyclin inhibition would also 
limit cell death as this would limit cell cycle progression (provided it was not toxic to 
healthy cells).
6.3.2 Kinases and the cell cycle
Inhibition o f JNK in both glutamate and untreated HT22 cells results in cell 
proliferation arrest and an aberrant increase in G2 population. One o f the possible 
explanations is that JNK contributes to G2/M progression by interacting with cyclin B, 
the active cyclin at that phase o f the cell cycle (see Figure 6.1). The interaction of 
JNK with cyclin B has previously been described in HeLa cells (Goss et al. 2003) 
where stressed cells activated JNK which phosphorylated and inactivated cyclin B. 
However as the model observed in this study requires JNK for G2/M transition in
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healthy cells this is unlikely to be the system employed here. Instead as .INK appears 
to play a role in cell cycle progression of healthy cells, the protective effect of 
SP600125 may be due to its ability to inhibit cell cycle progression rather than as a 
direct inhibition o f stress induced JNK activity. Indeed, stress induced apoptosis 
mediated by JNK is linked to cytochrome c release and caspase activation (Kuan et al. 
2003; Cao et al. 2004), features that were not observed in this system.
The requirement of JNK activity during cell cycle progression has previously been 
observed in fibroblast cell lines (Lallemand et al. 1998; Du et al. 2004) and revealed 
by primary JNK -/- cultures (Tournier et al. 2000) and in c-jun knockouts where an 
decreased cell proliferation was associated with G2 cell cycle arrest (Shaulian et al. 
2000). In the study by Du and co-workers (2004), inhibition o f JNK activity by 
SP600125 inhibited cellular proliferation and resulted in G2 arrest. JNK activity was 
observed during the G2/M indicating a role for JNK during the G2/M cell cycle 
checkpoint. Also in this study, Du and co-workers made the observation that JNK 
inhibited fibroblasts showed a similar morphology to those treated with inhibitors of 
spindle formation (Kung et al. 1990).
This apparent dependency o f glutamate toxicity on the cell cycle may also explain the 
observed increase in ERK activity following glutamate treatment in HT22 cells (Satoh 
et al. 2000; Stanciu et al. 2000; Levinthal and Defranco 2004). Where these 
investigations have shown ERK activity in glutamate treated cells, this may not 
necessarily mean that ERK has a death-related role in neurons. Instead, the activated 
ERKs observed in dying cells may be due to the cell cycle progression o f those cells,
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therefore inhibition o f ERK and subsequent inhibition o f cell death, by for example 
U0126 (Satoh et al. 2000), may again be an effect o f cell cycle inhibition.
In this model of HT22 cell death SB415286 resulted in an enhancement of G2 in 
untreated cells as well as those treated with glutamate suggesting some involvement 
o f SB415286 in the HT22 cell cycle. However, cell proliferation analysis only 
revealed significant inhibition o f cell division when SB415286 was used in 
combination with glutamate as compared to the proliferation o f HT22 cells with 
SB415286 alone, suggesting that GSK activity may contribute to the G2/M-cell death 
transition in this model. Previous data has indicated a role for GSK in the cell cycle 
by promoting the nuclear export o f cyclin D and allowing the cell to progress through 
S phase into G2 (Ryves and Harwood 2003). Furthermore GSK3p has been shown to 
be an upstream activator o f MEKK l which regulates JNK activation (Kim et al. 2003) 
which in this system appears to be required for G2/M progression. Therefore GSK 
may partly regulate MEKK l mediated activation of .INK and G2/M progression 
explaining the observed inhibition at G2 .
The enlarged morphology which accompanies the G2 arrest reveals that inhibition of 
cell cycle by SP600125 and SB415286 also inhibits chromatin condensation. This 
may (a) reveal that the condensation occurs after the initiation o f the cell death 
pathway, perhaps as a result o f altered mitosis or (b) that the inhibitors used here 
prevent chromatin condensation which then blocks cell death.
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6.3.3 Calpains and the cell cycle
The arrest in cell proliferation and the small but significant G2 arrest observed from 
ALLN treatment may highlight the requirement of calpain activity during cell cycle 
progression. Indeed, M-calpain has previously been shown to be required for 
progression through the cell cycle in myoblasts (Raynaud et al. 2004) and the calpain 
inhibitor PD150606 inhibited cell proliferation in myelo-erythroid leukaemic cells 
(Janossy et al. 2004). However, data from western blotting and Suc-LLVY-AMC 
cleavage indicated that the inhibition gained from ALLN was not due to simply 
inhibition o f the cell cycle but that calpain activity was increased following glutamate 
treatment which contributed to cell death. It is likely then that calpains play a role in 
the transition from cell cycle to cell death, and due to the observed G2 arrest it may be 
proposed that this takes place during the G2/M progression.
In a model o f Alzheimer’s disease, Veeranna et al (2004) showed ERK activation was 
mediated by calpain activity and furthermore showed that calpain mediated fodrin 
cleavage was present without caspase-3 activity. This model would suggest that 
calpains mediate re-entry into the cell cycle which could then result in a similar 
mechanism of cell death to the one observed here as it appears to be mediated by 
calpains with no caspase-3 activity^ The observed upregulation o f cell cycle activity 
by calpains in the Veeranna study may also explain the G2 cell cycle arrest observed 
from ALLN treatment in this HT22 system.
6.3.4 Why re-enter the cell cycle?
The data presented here and that discussed above gives evidence to suggest that 
neurodegeneration can involve re-entry to the cell cycle however, neuronal cells in
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vivo are terminally differentiated and as such do not continue to divide. In 1993 
Heintz suggested that neurodegeneration was a result of neurones attempting to re­
enter the cell cycle however, due to the lack o f cell cycle machinery the cell dies 
(Heintz 1993). More recently, upon the discovery o f activated cell cycle machinery in 
dying neurones, it has been proposed that neurons will activate cell cycle machinery 
perhaps to re-initiate cell cycle check points and repair damage to genetic material 
(Kruman 2004). The link to DNA replication has been illustrated by Kruman and co- 
workers (Kruman et al, 2004) who showed that chemical inducers o f DNA damage 
caused apoptosis associated with DNA replication whereas apoptotic inducers that did 
not target DNA resulted in apoptosis without DNA replication.
This research indicates that there is a role for cell cycle progression in neuronal cell 
death where DNA damage is present. This has implications for many 
neurodegenerative diseases including ischaemia where DNA damage has been found 
(Hou and MacManus 2002). However, upregulation o f the cell cycle is difficult to 
study in neurons due to their non-proliferative nature. This report has described an in 
vitro model o f neurodegeneration and provided a link with the cell cycle. It will be of 
interest to now investigate further the molecular mechanisms at work and link them to 
in vivo observations.
6.3.5 The Proposed Model of Oxidative Stress in HT22 cells
Figure 6.2 outlines the model of glutamate induced toxicity in HT22 cells as found by 
this study. Cell proliferation studies outlined in Figure 5.13 revealed that many o f the 
inhibitors used actually resulted in cell cycle inhibition which may account for their 
protective qualities. Amongst these was cycloheximide which provides another
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theory as to its ability to inhibit oxidative glutamate toxicity. Whereas previous 
studies have indicated that cycloheximide inhibits cell death by preventing 
intracellular cysteine conversion into proteins other than glutathione (Ratan et al. 
1994b) or preventing the production o f apoptotic/pro-death proteins (Tan et al. 1998a) 
here it may be proposed that the protective effect o f cycloheximide is via an inhibition 
o f cell proliferation. Significant inhibition o f cell proliferation was also observed 
with p-estradiol and glutamate, the inhibition o f proliferation was not as great as with 
other inhibitors such as cycloheximide which would suggest that P-estradiol is an 
antioxidant preventing initial ROS damage, and inhibiting the onset of cell cycle 
induced cell death allowing cells to replicate normally.
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Figure 6.2 The proposed model of glutamate induced toxicity in HT22 cells.
Upon exposure to high levels o f glutamate the cysteine/glutamate transporter is 
blocked, resulting in lowered intracellular glutathione (GSH) levels. A build up of 
ROS is partly attenuated by endogenous caspase activity. Excess ROS activity 
damages vital components of the cell which are detected during cell cycle 
progression, resulting in mitotic cell death. These effects are reversed by the use of 
techniques/compounds listed to the right.
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Interestingly, GSK3p inhibition although inhibiting cell cycle progression in 
combination with glutamate did not affect cell cycle progression alone suggesting that 
GSKSp provides a link between the cell cycle and cell death in oxidative glutamate 
toxicity. Previous data has shown both pro-apoptotic (Watcharasit et al. 2002; 
Schafer et al. 2004; Macanas-Pirard et al. 2005) and anti-apoptotic (Hoeflich et al. 
2000; Qu et al. 2004) roles for GSKSp. It has been suggested that one o f the pro- 
apoptotic mechanisms of GSK3p is through the tumour suppressor protein p53 which 
binds to and activates GSK3p which then promotes p53 activities such as caspase-3 
activity (Watcharasit et al. 2002). As oxidative glutamate toxicity does not involve 
caspase-3 activity it does not seem likely that a p53 mediated apoptotic pathway is 
activated which suggests that an alternative cell death pathway involving GSK3p is 
activated. However we cannot rule out the possibility of a caspase independent p53 
dependent pathway. One alternative mechanism of action is that GSK3p is 
responsible for the activation of MEKK l (see Figure 1.11) (Kim et al. 2003) which as 
a results activates downstream ERK and JNK pathways leading to cell death (Yujiri et 
al. 1998).
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6.4 The applications of this study
This study has investigated the death associated pathways responsible for oxidative 
and apoptotic cell death. It is thought that by investigating and identifying pathways 
o f neuronal cell death effective pharmaceutical treatments can be developed 
(Yakovlev and Faden 2004). Using these two model systems one could conclude that 
the majority o f caspase mediated damage is due to apoptotic like mechanisms initiated 
through pathways such as the CD95 death receptor. Furthermore, calpain and kinase 
mediated damage may be due to oxidative injury.
This study highlights the importance o f including the whole picture when identifying 
neuroprotective targets. For example in one injury there may be both apoptotic and 
oxidative stress at work therefore, the application o f caspase inhibitors, although 
limiting the apoptotic pathology may exacerbate underlying oxidative toxicities. If an 
overall inhibitory mechanism has been found from these two models o f ischaemic 
injuiy it is that inhibition o f death associated proteases other than caspases limit both 
CD95 and oxidative neuronal cell death. From this evidence it may be proposed that 
these are good pharmacological targets in the treatment o f neurodegeneration. 
Indeed, in a recent study in transgenic mice expressing specific inhibitors of calpains 
and caspases, overexpression o f the calpain inhibitor calpastatin resulted in limited 
neuropathologies whereas no limitation was observed from caspase inhibition 
(Higuchi et al. 2005).
It is important to stress that many o f the findings discussed from this study have been 
based on investigations using a cell line. The HT22 cell line was selected from the 
HT4 SV40 antigen immortalised hippocampal cell line (Morimoto and Koshland
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1990). Therefore many of the points discussed here would have to be confirmed 
using primary and in vivo based assays.
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6.5 Future Work
This study has investigated the biochemical pathways associated with cell death in a 
murine hippocampal cell line. Although links have been made between the models 
described here and in vivo work, the next step would be to replicate the effects 
observed here with primary neuronal work and/or in vivo studies.
The model of CD95 apoptosis in HT22 cells, although shown to involve the 
mitochondrial pathway, has not been concluded to be type I or type II from this work. 
Therefore studies using Bcl-2/Bcl X overexpression would be useful in determining 
whether this model of neurotoxicity was dependent on mitochondrial involvement.
Oxidative glutamate toxicity in this study has not only revealed a dependence on cell 
cycle progression but also that cell cycle progression in HT22 cells involves JNK 
activity. From this work it would be interesting to determine how JNK regulates cell 
cycle progression and how GSK is involved in linking cell cycle progression to cell 
death.
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7 CONCLUSIONS
• The DsRed-DEVD-EYFP FRET construct is a suitable marker for the 
detection o f active caspase-3 in living cells.
• Activation o f the CD95 death receptor in HT22 cells results in cell death 
associated with Bax activation, translocation, cytochrome c release and 
caspase activation.
• Glutamate induces a form o f HT22 cell death mediated by calpains and limited 
by caspase activity.
• Oxidative glutamate toxicity in HT22 cells is dependent on cell cycle 
progression.
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9 Appendix
FRET plasmid map
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